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ABSTRACT
Diabetic retinopathy (DR) is a prevalent cause of vision impairment and blindness among adults
in the United States. Early diagnosis of DR through dilated eye examinations can reduce the risk
of vision impairment or loss. Differences in eye examination rates by race and ethnicity have
been suggested by prior studies emphasizing importance of increasing insurance coverage and
access to care among minority populations. The Affordable Care Act aimed to expand health
insurance coverage and improve access to care. This study examined trends overall and by race
and ethnicity in eye examination rates and the contribution of Medicaid expansion on changes in
eye examination rates among U.S. adults with diabetes living below 138% of the federal poverty
level (FPL). This research utilized data from the 2010-2017 Medical Expenditure Panel Survey.
Univariate and multivariable logistic regression models with post-estimation commands were fit
to assess changes in eye examination rates overall, by race and ethnicity, and by residence in a
state that expanded or did not expand Medicaid, while controlling for predisposing, enabling, and
need factors, as conceptualized by the Andersen Healthcare Utilization model. Eye examination
rates did not significantly change among non-Hispanic whites, non-Hispanic blacks, and
Hispanics from 2010-2017. The fully adjusted model revealed no significant differences in eye
examination rates between the three racial and ethnic subgroups and in individuals with diabetes

living below 138% of the FPL in expansion vs non-expansion states. Between 2010 and 2017, no
significant improvements in eye examination were noted among non-Hispanic whites, nonHispanic blacks, and Hispanics, and Medicaid expansion was not associated with changes in eye
examination rates. Research on public health interventions targeting other factors that influence
eye screening is warranted as expanding access to insurance coverage alone did not appear to
translate into improvements in eye examinations.

INDEX WORDS: Diabetic retinopathy, Dilated eye examination, Racial and ethnic disparities,
Affordable Care Act, Medicaid expansion, MEPS.
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CHAPTER 1-INTRODUCTION
Background
The global diabetes prevalence in adults aged 20-79 years is estimated to be 9.3% in 2019
and is projected to rise to 10.9% by the year 2045 (Saeedi et al., 2019). In 2018, an estimated
34.2 million people of all ages or 10.5% of the United States (U.S.) population had diagnosed
diabetes. For U.S. adults 18+ years, the prevalence of diagnosed diabetes in 2018 was 13.0%
(34.1 million adults) (Centers for Disease Control and Prevention [CDC], 2020a). The diabetes
prevalence is projected to continue to rise over time as the U.S. population grows and ages
(American Diabetes Association [ADA], 2018).
Diabetes is a chronic condition characterized by high levels of blood glucose, which is a
sugar found in many foods. When food is digested and broken down, glucose is released and
absorbed into the intestines where it passes into the bloodstream. Insulin is a hormone made by
the pancreas that promotes the absorption of blood glucose into various cells of the body for
energy and storage. Diabetes develops when the body is either not able to produce insulin or is
not able to use insulin properly (Roglic, 2016). With type 1 diabetes, the immune system
destroys the cells in the pancreas that make insulin (National Institute of Diabetes and Digestive
and Kidney Diseases [NIDDK], 2017a). As a result, the body cannot make insulin, glucose can
no longer get into cells, and blood glucose levels rise above normal (NIDDK, 2017a). Type 1
diabetes most often occurs in children and young adults but can appear at any age. The risk of
developing type 1 diabetes may increase in individuals whose parent or sibling have type 1
diabetes (NIDDK, 2017a). Type 2 diabetes is the most common form of diabetes and occurs
when the body under-produces insulin or does not use insulin properly (NIDDK, 2017b). As a
result, glucose is not absorbed properly leading to high levels of glucose in the blood. Individuals
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are more likely to develop type 2 diabetes if they are age 45 or older, are African American,
Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific
Islander, have a family history of diabetes, live a sedentary lifestyle, are overweight or obese, or
have high blood pressure, low high-density lipoprotein cholesterol, high triglycerides, or
depression (NIDDK, 2016).
The continuous presence of excess blood glucose can lead to negative changes in the
blood vessels, and people with diabetes often develop diverse vascular-related complications that
can drastically reduce the quality of life (Boyle et al., 2010). A microvascular complication of
diabetes, diabetic retinopathy is the most prevalent cause of vision impairment and blindness
among working-age adults (i.e., those aged 20-74 years) in the U.S. and the fifth most common
cause of vision impairment and blindness in the world (CDC, 2018; Cheung et al., 2010; Leasher
et al., 2016; Mohamed et al., 2007). Diabetic retinopathy exists in several stages including early
and severe non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy
(PDR), and diabetic macular edema (DME) (Khandekar, 2012). Individuals with NPDR may not
exhibit any symptoms; however, those with PDR are at risk for blindness and/or other serious
morbidities (Khandekar, 2012). Approximately one in three people with diabetes aged 40 years
and above has some sign of the diabetic retinopathy (CDC, 2014; Zhang et al., 2010).
Progression from NPDR to PDR may occur over years of time. The Wisconsin Epidemiologic
Study of Diabetic Retinopathy (WESDR) found the incidence of PDR had increased from 0%
during the first 5 years of having diabetes to 27.9% during years 13–14 of diabetes and remained
stable after 15 years (Klein et al., 1984). Compared to individuals without diabetic retinopathy,
those with diabetic retinopathy may experience a lower quality of life. A study performed in a
diabetes patient population in India found that the quality of life was significantly lower in
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patients with diabetic retinopathy when compared with those without diabetic retinopathy with
maximum effect seen on general health, general vision and mental health (Pereira et al., 2017).
Furthermore, as the severity and duration of retinopathy increased, the quality of life decreased
(Pereira et al., 2017).
One way to reduce the risk of severe vision impairment or loss resulting from diabetic
retinopathy is through screening in the form of dilated eye examinations (ADA, 2019). Early
detection of diabetic retinopathy through screening can reduce severe vision loss by up to 94%
(Fathy, Patel, Sternberg, & Kohanim, 2016). In identifying the condition during screening,
timely and appropriate vision care (e.g., laser treatment, medications, and/or surgery) can prevent
or delay the onset of ocular morbidity, visual impairment, and blindness associated with diabetic
retinopathy (Khandekar, 2012; Paz et al., 2006). The ADA (2019) and the American Academy of
Ophthalmology (2019) recommend people with type 1 diabetes receive annual eye examinations
beginning 5 years after the onset of the disease, whereas people with type 2 diabetes have an eye
examination at onset of the disease and annually thereafter. However, in 2016, only 62.2% of
adults with diabetes reported having an annual screening for diabetic retinopathy (CDC, 2020b).
Problem Statement
Diabetic retinopathy has been shown to disproportionately affect racial and ethnic
minority populations. For example, non-Hispanic blacks and Hispanics are more likely to have
diabetic retinopathy compared with non-Hispanic whites (Carter et al., 1996; Golden et al.,
2012; Osborn et al., 2013). A study based on data from the 1988-1994 National Health and
Nutrition Examination Survey (NHANES) found in adults aged 40 years and older, the presence
of any diabetic retinopathy was 46% higher in non-Hispanic blacks and 84% higher in Mexican
Americans than non-Hispanic whites (Harris et al., 1998). Similarly, in a study based on data
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from the Veterans Affairs Diabetes Trial, macular edema was significantly more prevalent in
Hispanics (18%) and non-Hispanic blacks (15.6%) than in non-Hispanic whites (6.3%)
(Emanuele et al., 2009). Using 2005-2008 NHANES, a study of adults >=40 years of age with
diabetes found non-Hispanic blacks and Hispanic individuals had a higher crude prevalence of
diabetic retinopathy than non-Hispanic whites (38.8%, 34.0%, respectively, vs 26.4%) and a
higher crude prevalence of vision-threatening diabetic retinopathy, defined as the presence of
severe NPDR, PDR, or DME (9.3% and 7.3% respectively, vs 3.2%) (Zhang et al., 2010). In a
study of 312 people who visited a Model Demonstration Unit of the Washington University
Diabetes Research and Training Center, African Americans with type 1 diabetes were 1.86 times
more likely to develop PDR compared to whites (Arfken et al., 1998).
Additionally, some studies report differences in eye examination rates among racial and
ethnic groups (Chen et al., 2014; Lu et al., 2016; Shi et al., 2014; Tran et al., 2017). A study
based on the 2002-2013 Medical Expenditure Panel Survey (MEPS) data showed respondents of
Asian and Hispanic ethnicity had a 49% and 15%, respectively, lower likelihood of ever having
received a dilated eye examination when compared to non-Hispanic/non-Asian whites (Tran et
al., 2017). Lu et al., surveyed 101 African American or Hispanic diabetic patients from a safetynet clinic in Los Angeles to examine perceived barriers to screening (2016). Compared with
Hispanic patients, African American patients were screened 50% less often in the previous year,
despite reporting similar barriers to diabetic retinopathy screening (Lu et al., 2016).
Previous studies have identified various barriers to obtaining eye examinations with lack
of health insurance being identified as the most common barrier across studies (Ellish et al.,
2007; Lu et al., 2016; Owsley et al., 2006; Paz et al., 2006; Shi et al., 2014; Walker et al., 1997).
Racial and ethnic minority populations are less likely to be insured compared to whites (Andrulis
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et al., 2010; Rowland & Shartzer, 2008; Office of the Assistant Secretary for Planning and
Evaluation [ASPE], 2012). Uninsured individuals are more likely to have unmet medical needs
and fare worse in health outcomes compared to insured individuals (Clemans-Cope et al., &
Blavin, 2012; Hadley, 2003; Institute of Medicine, 2001).
The Affordable Care Act (ACA) aimed to extend health insurance coverage
predominantly through the following initiatives: expansion of Medicaid eligibility to nearly all
adults with incomes up to 138 percent of the federal poverty level (FPL) (previous eligibility was
limited to specific low-income groups, such as the elderly, people with disabilities, children,
pregnant women, and some parents; the eligibility varies from state to state); establishment of
health insurance exchanges for small employers (e.g., ≥50 employees) and individuals
purchasing private coverage with subsidies for individuals with incomes at 138-400 percent of
the FPL; and requirement that US citizens and legal residents have qualifying health coverage or
pay a tax penalty (Clemans-Cope et al., 2012; The Henry J. Kaiser Family Foundation [KFF],
2012, 2020).
Recent studies have demonstrated that racial and ethnic disparities in insurance coverage
and access to care have been reduced since ACA implementation (Buchmueller et al., 2016;
Chen et al., 2016; Monnette et al., 2019; ASPE, 2016). However, further research is warranted
on whether increased insurance coverage translates into improved health practices and outcomes.
Purpose
The purpose of this study was to examine trends in eye examination rates among U.S.
adults with diabetes overall and by race and ethnicity and to examine the contribution of the
ACA Medicaid expansion to changes in eye examination rates between 2010-2017.
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Research Questions
RQ1: Are there racial and ethnic disparities in eye examination rates among U.S. adults
(age≥18 years) with diabetes across 2010-2017?
RQ2: Is ACA Medicaid expansion associated with changes in eye examination rates
among U.S. adults with diabetes living below 138% of the federal poverty level (FPL)?
Significance
Racial and ethnic disparities in utilization of health care services and health outcomes
have been well-documented in the U.S. Minority populations encompass smaller groups of
people who may be discriminated against in society and differ from the majority population by
race, ethnicity, religion, language or political affiliation (Humes et al., 2011). In a country that is
predominantly white, racial minority populations in the U.S. include blacks or African
Americans, Native Americans and Alaskan Natives, Asian Americans, and Native Hawaiian and
Other Pacific Islanders. The largest minority ethnic group in the U.S. is Hispanics and Latinos;
however, additional ethnic groups such as Jews and Arabs are also present in the U.S (Humes et
al., 2011). The overarching goals of the Healthy People 2020 was to eliminate disparities,
achieve health equity, and improve health for all groups (Office of Disease Prevention and
Health Promotion [ODPHP], 2020a). However, achieving such goals requires a multifaceted
approach that addresses individual-, sociocultural-, environmental-, and system-level factors.
Through expanding access to insurance coverage, improving health care delivery, and reducing
costs associated with care, the ACA aimed to address system-level barriers to care.
There are varied reports in the literature regarding whether ACA implementation
translates to improved health practices, particularly for preventive care use (Adams et al., 2018;
Agirdas & Holding, 2018; Hong et al., 2017; Lee et al., 2019; Lau et al., 2014). A quasi-
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experimental study of Medical Expenditure Panel Survey (MEPS) data that examined whether
ACA was associated with increased preventive care service use among privately insured adults
(aged 18-64 years) found ACA implementation was associated with increases in routine checkups and influenza vaccinations among those privately insured compared to those without
insurance (Hong, et al., 2017). However, the ACA was not associated with changes in blood
pressure check, cholesterol check and cancer screenings (pap smear test, mammography, and
colorectal cancer screening) (Hong et al., 2017). A similar quasi-experimental study of MEPS
data examined whether ACA’s free preventive care benefits were associated with a reduction in
racial and ethnic disparities in the utilization of preventive care use. This study found that
privately insured Hispanics and privately insured Blacks had an increased probability of
obtaining a colonoscopy and mammogram compared to non-Hispanic whites on Medicaid.
However, this study did not find any significant improvements for any racial or ethnic group for
cholesterol screenings or Pap smears (Agirdas & Holding, 2018). Similar findings of ACA being
associated with improvements in use of some preventive care services but not others were seen
in quasi-experimental studies of U.S. women adult (19-64 years) populations (Lee et al., 2019)
and U.S. adolescent (18-25 years) populations (Lau et al., 2019).
Outside of system-level barriers to obtaining eye examinations, many other factors such
as lack of knowledge regarding need for eye examination, lack of transportation, or lack of local
optometrists or ophthalmologists can influence whether an individual with diabetes obtains an
eye examination (Roy, 2004; Walker et al., 1997). These other factors can have a stronger
influence on screening behavior than health insurance does; therefore, gaining health insurance
through ACA implementation may not translate into increased eye examination rates. The
findings of this study will provide evidence on how disparities in eye examination rates have
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changed over time and the ACA’s role in addressing racial and ethnic disparities in eye
examination rates.
Definition of Terms
The following terms are used throughout this research:
Diabetes- A metabolic disorder in which the body has high sugar levels for prolonged periods of
time. May present in various forms such as type 1 (pancreas produces little or no insulin) or type
2 (pancreas produces insufficient insulin or body does not use insulin properly). (NIDDK,
2017a)
Diabetic retinopathy- A microvascular complication of diabetes that affects the eyes. (Mayo
Clinic, 2018)
Non-proliferative diabetic retinopathy (NPDR)- A stage of diabetic retinopathy that is
characterized by leaky blood vessels. (Khandekar, 2012)
Proliferative diabetic retinopathy (PDR)- A stage of diabetic retinopathy that is characterized by
growth of new blood vessels on the retina. (Khandekar, 2012)
Vision-threatening diabetic retinopathy- Includes severe non-proliferative diabetic retinopathy,
proliferative diabetic retinopathy, and diabetic macular edema. (Zhang et al., 2010)
Diabetic macular edema (DME)- May accompany any stage of diabetic retinopathy and is
characterized by fluid buildup in the macula which is the part of the retina that controls detailed
vision abilities. (Khandekar, 2012)
Vision impairment- Defined as a functional limitation of the eye or eyes that cannot be corrected
with standard glasses or contact lenses and reduces a person's ability to function at certain or all
tasks. (National Academies of Sciences, Engineering, and Medicine [NASEM], 2016)
Blindness- Defined as a visual acuity worse than 20/400. (NASEM, 2016)
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Dilated eye examination- Physical examination of the eyes that involves the administration of
eye drops to dilate pupils in order to allow more light into the eye. During eye examination,
optometrist/ophthalmologist assess for abnormalities with the anatomy and functioning of the
eye(s). (National Eye Institute, 2019)
Racial minority- A group of people from a different race living in a country or area where the
majority of people are of a different race. (Pollard & O'Hare, 1999)
Ethnic minority- A group of people from a different nationality or ethnicity living in a country or
area where the majority of people are of a different nationality or ethnicity. (Pollard & O'Hare,
1999)
Health disparity- A particular type of health difference that is closely linked with economic,
social, or environmental disadvantage. Health disparities adversely affect groups of people who
have systematically experienced greater social or economic obstacles to health based on their
racial or ethnic group, religion, socioeconomic -status, gender, age, or mental health; cognitive,
sensory, or physical disability; sexual orientation or gender identity; geographic location; or
other characteristics historically linked to discrimination or exclusion. (ODPHP, 2020a)
Health insurance coverage- Coverage that provides for the payments of benefits as a result of
sickness or injury. It includes insurance for losses from accident, medical expense, disability, or
accidental death and dismemberment (Caxton, 2017)
Affordable Care Act- Health reform legislation signed into law by President Barack Obama in
March 2010 that extended health insurance coverage through the expansion of Medicaid
eligibility and through establishment of health insurance exchanges for small employers (e.g.,
≥50 employees) and individuals purchasing private coverage (Clemans-Cope, 2012; KFF, 2012,
2020; H.R. 3590, 2010).
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Medicaid expansion- Expansion of Medicaid eligibility to nearly all adults with incomes up to
138 percent of the federal poverty level (FPL). Previous eligibility varied from state to state but
was limited to specific low-income groups, such as the elderly, people with disabilities, children,
pregnant women, and some parents. (KFF, 2012, 2020)
Federal poverty level- Defined as the minimum annual income required to avoid living in
poverty in the U.S. (ASPE, 2020)
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CHAPTER 2-LITERATURE REVIEW
Chapter 2 provides an extensive review of the literature and research on diabetic
retinopathy, eye screening, and the Affordable Care Act. The chapter is divided into sections
that include an overview of diabetic retinopathy including disease burden, screening and
treatment recommendations and costs, factors influencing screening, conceptual framework, the
role of health insurance in addressing racial and ethnic disparities, and an overview of the
Affordable Care Act.
Out of all the human senses, vision is the most highly developed. It plays an important role
in the way humans interact with the environment around them. It is important for learning skills
and devices, moving around, and protecting us from danger (American Academy of
Ophthalmology, 1987). Therefore, the loss of vision can greatly impact the affected individuals,
as well as their friends and family. The weakening or loss of vision can impair an individuals’
ability to completely care for themselves and subsequently, can result in the need for a caretaker.
Vision loss can affect many aspects of an individual’s life such as the quality of life (QOL),
independence, mobility, mental health, cognition, social function, employment, and educational
attainment (National Academies of Sciences, Engineering, and Medicine, 2016). In a study using
Behavioral Risk Factor Surveillance System (BRFSS) data from 22 states, researchers examined
health-related QOL among individuals ages 40 to 64 years by visual impairment status and found
the percentage of individuals reporting life dissatisfaction, fair or poor reported health, physical
and mental unhealthy days, and days of limited activity increased as the self-reported severity of
vision impairment increased (Crews et al., 2016; National Academies of Sciences, Engineering,
and Medicine, 2016). Furthermore, QOL was shown to slowly decline with the onset of vision

19
loss and then decreased more quickly as measures of visual field defects increased (Rein et al.,
2007).
Vision impairment can create challenges for any individual, and the diabetes population is
no exception as individuals with diabetes are susceptible to a plethora of vision-related
complications. Not being able to see well can affect various vision-reliant tasks for individuals
with diabetes. Tasks required for diabetes management such as self-care (e.g., foot checks,
checking blood glucose levels, preparing nutritious meals) and transportation (e.g., getting to and
from clinic visits) can be greatly hindered by impaired vision (NASEM, 2016). Additionally,
vision impairment can affect the individual’s ability to be compliant with medication adherence
and management (e.g., reading pill bottles, self-administering insulin injections or eye drops).
Therefore, individuals with diabetes who develop vision loss experience more challenges to
successfully managing their condition (NASEM, 2016). Furthermore, individuals with diabetes
tend to suffer from coexisting morbidities (e.g., obesity, cardiovascular disease) that can further
worsen their health, and are at risk for developing several different complications including
diabetic retinopathy.
Diabetic Retinopathy
Epidemiology and Risk Factors
Diabetic retinopathy is a common complication of both type 1 and type 2 diabetes. To
examine the global prevalence and major risk factors of diabetic retinopathy, Yau et al. (2012)
performed a pooled meta-analysis of 35 population-based studies conducted from 1980-2008 in
the U.S., Asia, Australia, and Europe. Based on the findings of this analysis, the overall global
prevalence of any diabetic retinopathy (defined as presence of NPDR, PDR, DME, or any
combination thereof) was 34.6%, and the overall global prevalence of PDR and DME was 7.0%
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and 6.8%, respectively. Pooled analysis of the studies found that the age-standardized prevalence
of any diabetic retinopathy was highest among African Americans and lowest among Asians.
Longer diabetes duration, higher blood pressure, higher HbA1c levels, and type 1 diabetes were
associated with higher prevalence of diabetic retinopathy (Yau et al., 2012). However, studies
have shown that maintaining optimal glycemic levels, blood pressure levels, and serum lipid
levels can reduce the risk or slow the progression of diabetic retinopathy (Chew et al., 2014;
Estacio et al., 1998; Klein, 1995; Leske et al., 2005).
At present, a national surveillance system for reporting diabetic retinopathy exists neither
in the U.S. nor in other countries. The most current national estimate of diabetic retinopathy
prevalence comes from the National Health and Nutrition Examination Survey (NHANES).
Using data from the 2005-2008 NHANES, Zhang et al. (2010) estimated the prevalence of
diabetic retinopathy and vision-threatening diabetic retinopathy (i.e., defined as the presence of
severe NPDR, PDR, or DME) among people with diabetes aged 40 years and older was 28.5%
and 4.4%, respectively. The prevalence among the overall U.S. population during that time
period was 3.8% for diabetic retinopathy and 0.6% for vision-threatening diabetic retinopathy
(e.g., severe NPDR, PDR, and DME). Significant risk factors for diabetic retinopathy that were
identified included male sex, higher hemoglobin A1c (HbA1c) level, longer duration of diabetes,
and higher systolic blood pressure (Zhang et al, 2010).
Another population-based study based on a regional cohort was conducted to examine the
incidence of diabetic retinopathy. A longitudinal study, the Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR) consisted of a sample of patients with diabetes who received
primary care in an 11-county area in southern Wisconsin from 1979 to 1980 (Klein et al., 1998).
The sample consisted of individuals with either type 1 or type 2 diabetes. Participants were
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assessed at baseline and followed for 4, 10, 14, and 25 years. Numerous reports regarding the
incidence and progression of diabetic retinopathy and DME have been generated from the study.
In a WESDR report of individuals with type 1 diabetes, the 14-year incidence of any diabetic
retinopathy was 95.9% and the 14-year incidence of DME was 26.1% (Klein et al., 1998). For
patients with diabetic retinopathy at baseline, 36.8% had progressed to PDR (Klein et al., 1998).
Women, individuals with higher HbA1c, and individuals with higher diastolic blood pressure
were at greater risk for diabetic retinopathy progression. Individuals with higher HbA1c, with
higher systolic and diastolic blood pressures, and with hypertension and proteinuria were at
higher risk for developing PDR. (Klein et al., 1998). Factors associated with increased incidence
of DME included severe baseline retinopathy, higher HbA1c at baseline, and presence of gross
proteinuria at baseline. In subgroup analysis, the study assessed the relationship between the age
and duration of diabetes at baseline and the 14-year progression of any diabetic retinopathy, 14year progression to PDR, and 14-year incidence of DME. A significant inverse relationship was
found between age at baseline examination and progression of any diabetic retinopathy with the
highest rate found in individuals ≤19 years of age and the lowest rate found in individuals ≥35
years of age. The 14-year progression to PDR was found to be significantly associated with the
duration of diabetes at baseline. Persons with ≥10 years of diabetes at baseline were 1.97 times
more likely to develop PDR and DME over the 14 years follow-up compared to persons with
<10 years of diabetes at baseline (Klein et al, 1998). The study did not include subgroup analysis
by race and ethnicity.
Disease Burden
Diabetic retinopathy is recognized as a major cause of blindness and visual impairment
worldwide. To estimate the number of people affected by blindness and visual impairment,
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Leasher et al. (2016) conducted a meta-analysis of global population-based studies that included
data from 1990-2010. Some of the areas represented in the study included Pacific Asia,
Australasia, Caribbean, Central, Eastern, and Western Europe, Andean, Central, Southern, and
Tropical Latin America, Oceania, North American, and Sub-Saharan Africa. Analyses revealed
that diabetic retinopathy accounted for 2.6% (833,690) of blindness and 1.9% (3.7 million) of
visual impairment (Leasher et al., 2016). Diabetic retinopathy-related blindness increased by
27% and diabetic retinopathy-related visual impairment increased by 64% from 1990 to 2010.
Further analysis revealed that of all global blindness causes, the percentage caused by diabetic
retinopathy increased from 2.1 in 1990 to 2.6% in 2010 (Leasher et al., 2016).
Although diabetic retinopathy is primarily associated with causing visual impairment and
blindness, it can also be an indicator for other systemic vascular complications. Findings from
the Framingham Heart and Eye Study indicated individuals with diabetes who had microvascular
disease (e.g., diabetic retinopathy) were more likely to have macrovascular disease (e.g.,
cardiovascular disease) (Hiller et al., 1988). Both NPDR and PDR have been linked with
conditions such as stroke, coronary heart disease, heart failure and nephropathy (Wong et al.,
2001). Furthermore, diabetic retinopathy has been associated with an increased risk of mortality,
particularly in individuals with cardiovascular risk factors (Cheung & Wong, 2008). In a pooled
analysis of 17 prospective, observational studies, results revealed that in patients with type 2
diabetes, the odds for all-cause mortality and/or cardiovascular events were 2.34 times as high
for patients with diabetic retinopathy compared to patients without diabetic retinopathy.
Similarly, for patients with type 1 diabetes, the odds for all-cause mortality and/or cardiovascular
events were 4.1 times as high for patients with diabetic retinopathy compared to patients without
diabetic retinopathy (Kramer et al., 2011).
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Screening
As diabetic retinopathy can progress with few or no visual symptoms, it is important that
individuals with diabetes receive adequate eye screening for early detection and subsequent
intervention. The aim of early detection through screening is to discover and treat conditions
which have already produced pathological change, but which have not reached a stage where
medical aid has been sought spontaneously (Wilson et al., 1968). Diabetic retinopathy is optimal
for screening because it is asymptomatic until advanced, highly prevalent, relatively easy to
detect, and confined to a well-defined population (people with diabetes) (Wong et al., 2016).
Furthermore, screening methods for diabetic retinopathy are relatively inexpensive, noninvasive, and there are clear treatment modalities for treating both early stage diabetic
retinopathy and DME that can prevent further progression and subsequent harm (ADA, 2019;
Wong et al., 2016). Research has shown that screening is effective in detecting diabetic
retinopathy and preventing blindness (ADA, 2019; Ding & Wong, 2012; Fong et al., 2001;
Singer et al., 1992; Solomon et al., 2017).
For adults with type 1 or type 2 diabetes, the ADA makes the following screening
recommendations:
Adults with type 1 diabetes should have an initial dilated and comprehensive eye
examination by an ophthalmologist or optometrist within 5 years after the onset of
diabetes.
Patients with type 2 diabetes should have an initial dilated and comprehensive eye
examination by an ophthalmologist or optometrist at the time of the diabetes
diagnosis.
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If there is no evidence of retinopathy for one or more annual eye exam and
glycemia is well controlled, then exams every 1–2 years may be considered. If
any level of diabetic retinopathy is present, subsequent dilated retinal
examinations should be repeated at least annually by an ophthalmologist or
optometrist. If retinopathy is progressing or sight-threatening, then examinations
will be required more frequently
Telemedicine programs that use validated retinal photography with remote
reading by an ophthalmologist or optometrist and timely referral for a
comprehensive eye examination when indicated can be an appropriate screening
strategy for diabetic retinopathy (ADA, 2019, p. 129).
Treatment
The purpose of diabetic retinopathy screening is to identify individuals who may be at
increased risk for developing a visual impairment or vision loss. Timely identification of signs
and symptoms of diabetic retinopathy reduces an individual’s chances of worsening the
condition through appropriate treatment. Current treatments for diabetic retinopathy including
laser photocoagulation and anti-vascular endothelial growth factor (anti-VEGF) injections can
reduce the risk of vision loss through disease regression. Panretinal photocoagulation for PDR
involves placing laser burns over the entire retina to promote regression and arrest progression of
retinal neovascularization (Cheung et al., 2010). In a clinical trial of over 1,758 patients with
PDR, the Diabetic Retinopathy Study (DRS) found panretinal photocoagulation reduced the risk
of severe visual loss by 50% over 5 years ("Photocoagulation treatment of proliferative diabetic
retinopathy. Clinical application of Diabetic Retinopathy Study [DRS] findings, DRS Report
Number 8. The Diabetic Retinopathy Study Research Group," 1981). Similarly, in a clinical trial
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of 3,711 patients with less severe diabetic retinopathy, the Early Treatment Diabetic Retinopathy
Study (ETDRS) found early administration of the therapy reduced the risk of progression to PDR
by 50% ("Focal photocoagulation treatment of diabetic macular edema. Relationship of
treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS
report no. 19. Early Treatment Diabetic Retinopathy Study Research Group," 1995). For
treatment of DME, photocoagulation is used to target individual leaky blood vessels near the
macula. The ETDRS found a 50% reduction in the risk of visual loss from clinically significant
DME after macular laser treatment ("Focal photocoagulation treatment of diabetic macular
edema. Relationship of treatment effect to fluorescein angiographic and other retinal
characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study
Research Group," 1995).
Although laser photocoagulation is considered the standard ocular treatment for diabetic
retinopathy and DME, ocular injection of anti-VEGF has been introduced as an alternative
treatment method. A randomized clinical trial of 305 adults with PDR demonstrated intravitreal
injections of an anti-VEGF agent, specifically ranibizumab, resulted in visual acuity outcomes
that were not worse than outcomes observed in patients treated with panretinal photocoagulation
at 2 years of follow up (Writing Committee for the Diabetic Retinopathy Clinical Research et al.,
2015). Additional outcomes observed for the ranibizumab treatment group were less peripheral
visual field loss, fewer vitrectomy surgeries for secondary complications from their proliferative
disease, and a lower risk of developing DME (ADA, 2019; Writing Committee for the Diabetic
Retinopathy Clinical Research et al., 2015).
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In cases where NPDR, PDR or DME is detected through screening, patients should be
referred to an ophthalmologist who is knowledgeable and experienced in the management of
diabetic retinopathy (ADA, 2019). The ADA provides the following guidelines for treatment:
Promptly refer patients with any level of macular edema, severe nonproliferative
diabetic retinopathy (a precursor of proliferative diabetic retinopathy), or any
proliferative diabetic retinopathy to an ophthalmologist who is knowledgeable
and experienced in the management of diabetic retinopathy.
The traditional standard treatment, panretinal laser photocoagulation therapy, is
indicated to reduce the risk of vision loss in patients with high-risk proliferative
diabetic retinopathy and, in some cases, severe non-proliferative diabetic
retinopathy.
Intravitreous injections of anti–vascular endothelial growth factor ranibizumab are
not inferior to traditional panretinal laser photocoagulation and are also indicated
to reduce the risk of vision loss in patients with proliferative diabetic retinopathy.
Intravitreous injections of anti–vascular endothelial growth factor is indicated for
central-involved diabetic macular edema, which occurs beneath the foveal center
and may threaten reading vision. (ADA, 2019, p 129)
Costs
Studies have shown that diabetics with retinopathy have significantly higher medical
costs than those without retinopathy (Schmier et al., 2009; Zhang et al., 2017). A recent study
performed in Singapore of adults (21-90 years) with type 2 diabetes found that the median of
total costs in individuals with diabetic retinopathy was significantly higher than that in
individuals without diabetic retinopathy. Further, costs increased with increasing severity of
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diabetic retinopathy with cost ratios of 1.1, 1.8, 2.0, and 2.3 for mild, moderate, severe NPDR,
and PDR, respectively, relative to non-diabetic retinopathy respectively (Zhang et al., 2017). A
U.S. study that analyzed Medicare claims data of diabetic beneficiaries with NPDR or PDR to
diabetic beneficiaries with no evidence of diabetic retinopathy reported similar findings (Schmier
et al., 2009). Their study of diabetic adults (≥65 years) found that the annual average costs for
both all care and ophthalmic care were significantly higher for beneficiaries with NPDR or PDR
compared to beneficiaries without diabetic retinopathy (Schmier et al., 2009). They also found
that average payments for all care and for ophthalmic care were substantially higher for PDR
cases compared to NPDR cases (Schmier et al., 2009). Early detection and treatment of diabetic
retinopathy has the potential to significantly reduce diabetes-related medical costs.
Many studies have used computer simulation modeling to evaluate the cost-effectiveness
of screening and treatment for diabetic retinopathy (Crijns et al., 1999; Javitt et al., 1994; Javitt
et al., 1996; Jones et al., 2010; Polak et al., 2003). Using data from U.S. population-based
epidemiological studies and clinical trials, along with data on federal budgetary costs of
blindness, Javitt et al. (1994) estimated the current and potential federal savings resulting from
the screening and treatment of and treatment of retinopathy in patients with type II diabetes.
Screening and treatment of diabetic retinopathy resulted in projected savings of $247.9 million to
the federal budget and 53,986 person-years of sight (Javitt et al, 1994). This study projected that
enrolling each additional person with type II diabetes into currently recommended
ophthalmological care would result in an average net savings of $975/person (Javitt et al, 1994).
Additional studies have also examined the cost-effectiveness of diabetic retinopathy
screening and treatment in terms of prevented blindness or years of avoided sight loss. A study
based in the Netherlands simulated the progression of diabetic retinopathy in a population of
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20,000 patients. The study found that in younger onset (<25 years) patients, screening reduced
the prevalence of blindness by 52%; however, little benefit was seen from screening in terms of
reduction in blindness later onset (>75 years) patients (Crijns et al., 1999). In a similar study that
modeled the cost-effectiveness of ophthalmological care (screening and treatment) in relation to
the progression of diabetic retinopathy, different scenarios of ophthalmological screening were
used to determine their cost-effectiveness in preventing blindness due to diabetic retinopathy
(Polak et al., 2003). Also performed in the Netherlands, the study found that screening was most
cost-effective in patients with earlier onset of diabetes. For patients with age of onset of 15 years,
the simulation model found that those who received screening frequently (i.e., 1 year if no
diabetic retinopathy present, twice a year if any diabetic retinopathy present, and 4 times a year if
ME or PDR present) had a lifetime sight gain of 532 years/1000 patients when compared to those
who did not receive screening. This rate diminished with increasing age in those with an onset of
35 years, 50 years, and 65 years and their lifetime sight gain was 125 years/1000 patients, 63
years/1000 patients, and 16 years/1000 patients, respectively (Polak et al., 2003).
Factors Influencing Diabetic Retinopathy Screening
As with any health behavior, there are many factors that can influence whether an
individual obtains diabetic retinopathy screening. The literature reports mixed findings on race
and ethnicity as a contributing factor to diabetic retinopathy screening. In adjusted analyses of
2002-2013 MEPS data, Tran, et al. (2017) found that the non-Hispanic whites were more likely
than Asians to report having an eye examination but did not find a significant difference in eye
examination rates between non-Hispanic whites and other minority groups (i.e., Hispanics and
non-Hispanic blacks). Contrastingly, Chen et al. (2014) found in adjusted analyses that both nonHispanic blacks and Hispanics were more likely than non-Hispanic whites to report having an
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eye examination. Shi et al. (2014) reported the opposite in that non-Hispanic whites were more
likely to have dilated eye examinations compared to minority populations (i.e., all other nonHispanic whites including blacks, Hispanics, American Indian/Alaska native, Asian, native
Hawaiian/Pacific islander, or multiple races).
In addition to race and ethnicity, other sociodemographic factors such as age, education,
sex, marital status, income and insurance status have also been associated with diabetic
retinopathy screening. Population-based studies of 2002-2009 MEPS data (Shi et al., 2014),
2001-2010 BRFSS data (Chen et al., 2014), and 2014-2015 MEPS data (Monnette et al., 2019)
found that older individuals (aged ≥45 years) were more likely to report receiving an eye
examination compared to younger individuals (aged<45 years). Education level was also shown
to influence screening as the likelihood of obtaining an eye examination increased with
increasing levels of education. Individuals with no high school diploma were less likely to obtain
an eye examination compared to individuals with a high school diploma (Chen et al, 2014;
Monnette et al., 2019; Shi et al. 2014; Tran et al., 2017), bachelor’s degree (Monnette et al.,
2019; Tran et al., 2017), or professional degree (Tran et al., 2017). Women and
married/partnered individuals were also more likely to report receiving an eye examination
(Chen et al., 2014; Monnette et al., 2019; Tran et al., 2017). Lastly, additional socioeconomic
factors found to be associated with eye examination were income ≥400 of the federal poverty
level (FPL) (Tran et al., 2017) or income >$50,000 (Chen et al, 2014) and having either private
or public insurance (Chen et al, 2014; Monnette et al., 2019; Shi et al. 2014; Tran et al., 2017).
Other health and health care-related factors found to be positively associated with eye
examinations were having a usual provider (Chen et al., 2014; Tran et al., 2017) and insulin use
(Chen et al., 2014). Duration of diabetes was shown to be positively associated with diabetic
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retinopathy prevalence and thus, might influence eye examination utilization (ADA, 2019;
Solomon et al., 2017; Zhao et al., 2014).
In addition to factors that may increase the likelihood that an individual obtains diabetic
retinopathy screening, several barriers to screening have also been identified. While there are
many approaches to categorizing barriers, in a review of the literature, Nsiah-Kumi, Ortmeier,
and Brown (2009) identified patient-, provider-, and health care system-related barriers to
screening decisions. A common patient-level theme identified in the literature was a lack of
knowledge and understanding of diabetic retinopathy, diabetic retinopathy screening, and
diabetic retinopathy treatment (Hartnett, Key, Loyacano, Horswell, & Desalvo, 2005; NsiahKumi et al., 2009; Schoenfeld, Greene, Wu, & Leske, 2001; Walker et al., 1997). Studies found
that patients did not understand the rationale for obtaining annual eye exams (Hartnett et al.
2005) and did not believe they were necessary (Roy, 2004; Schoenfeld et al., 2001). Additional
barriers identified were that patients had never been told by their physician to have an annual eye
exam (Roy, 2004; Walker et al., 1997) or patients had been unaware of or lacked eye-related
symptoms (Hartnett et al. 2005; Roy, 2004; Walker et al., 1997). Affordability and being too
busy to schedule an appointment were also identified as barriers to obtaining an eye examination
(Hartnett et al., 2005; Moss et al., 1995; Roy, 2004; Walker et al., 1997). For non-Englishspeaking Hispanics, for example, language barriers, and access to specialty care have been
identified as obstacles to obtaining recommended screening (Kirk et al., 2008; Nsiah-Kumi et al.,
2009).
Along with patient factors, provider-related factors have also been identified as barriers
to diabetic retinopathy screening. These include lack of awareness about screening guidelines
and lack of skills or equipment to perform eye exams (Walker et al., 1997). Contributors to poor
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screening completion rates include inadequate patient education (Moss et al., 1995; Walker et al.,
1997), poor patient-physician communication (Chin et al., 2001; Hartnett et al., 2005), and
insufficient appointment time with providers (Chin et al., 2001; Nsiah-Kumi et al., 2009). In a
population-based study of patients and their physicians, Mukamel et al. (1999) explored various
barriers to compliance with diabetic retinopathy screening guidelines. A significant factor
identified that influenced the probability of screening was the average number of primary care
physician visits each patient had. For patients who visited their primary care physician more
often, the probability of screening was significantly higher, suggesting that more contact with the
primary care physician may lead to more time for interaction and education of the patient
(Mukamel et al., 1999; Nsiah-Kumi et al., 2009).
System-level factors include lack of insurance coverage, long wait times for
appointments, and difficulties in scheduling appointments (Hartnett et al., 2005; Nsiah-Kumi et
al., 2009; "Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application
of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic
Retinopathy Study Research Group," 1981). In a study of a Latino population, those with lack of
health care coverage were twice as likely to not have visited the doctor in the previous year nor
have had an eye exam (Varma et al., 2004). Additionally, understaffing and high turnover of
specialized physicians such as optometrists and ophthalmologists contribute to poor screening
completion (Silver et al., 2006).
In Shi’s et al. study (2014), health insurance coverage was identified as a strong predictor
for receiving an eye examination. However, not all types of health insurance coverage are
created equal in that some plans contain benefits that others do not. Lack of certain benefits, such
as coverage for specialists including ophthalmologists and optometrists, who often perform eye
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examinations, can directly affect an individual’s self-monitoring behavior of obtaining
preventive screenings. In Shi et al. study (2014), the researchers observed insurance coverage
decreased over the years with minorities being affected to a larger degree than non-Hispanic
whites. However, even within the insured population, minorities still obtained eye examinations
to a lesser extent than non-Hispanic whites. Hence, it is possible that insurance coverage alone
may not fully address the racial and ethnic disparity seen in eye examination rates. The authors
surmise that in addition to health insurance coverage, other factors could contribute to the
disparities seen in diabetic retinopathy screening in this study. For example, patient’s attitudes
toward screening or referral by a health care provider are factors that can affect the uptake of
diabetic retinopathy screening services (Van Eijk et al., 2012). Additionally, the geographical
distribution of ophthalmologists and optometrists may also affect diabetic retinopathy screening
as in the areas with fewer ophthalmologists and optometrists, fewer dilated eye examinations
may be performed (Chou et al., 2012; Gable et al., 2000).
Further supporting this idea that other factors can contribute to screening, a crosssectional study of insured veterans at 21 Veteran Affairs’ facilities reported that a significantly
lower percentage of black patients had received a dilated eye examination in the past year
compared to white patients (Heisler et al., 2003). Even after adjusting for several covariables
(patients’ age, education, income, insulin use, diabetes self-management, duration, severity,
comorbidities, and health services utilization), the racial differences in receipt of eye
examinations persisted (Heisler et al., 2003). Considering that all participants in the study were
insured, these findings highlight the need to examine other health care system factors when
examining racial and ethnic differences in rates of eye exams. In this study, nearly all the racial
disparity in receipt of eye examination was explained by blacks disproportionately receiving care
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at facilities with poorer performance on that quality measure suggesting that improving the rate
of screening at low-performing facilities may improve racial disparities in eye care (Heisler et
al., 2003).
Andersen Healthcare Utilization Model
The multitude of factors that have been associated with screening have been categorized
in different ways. For example, prior studies have characterized them as patient-level, providerlevel or system-level factors. One approach to characterizing influencing factors is through the
Andersen Healthcare Utilization model. The model was created by Ronald Andersen in 1950 and
has been used in health behavioral studies to predict and explain use of health services. The
model suggests that health service utilization is determined by the individual’s propensity to use
or not use services (predisposing factors), facilitators or impediments to use of service (enabling
factors) and needs or perceived need for care (need factors) (Andersen et al., 2013; Lee et al.,
2018). The model has evolved over time to include contextual determinants of health services
utilization which can include organization and provider-related factors as well as community
characteristics (Andersen et al., 2014).
The variables that were considered to operationalize the Andersen Healthcare Utilization
model are depicted in Figure 2.1. Consistent with the literature review provided earlier in this
chapter, predisposing factors explored in this study will include age, sex, marital status, and
education. Enabling factors will include economic status as a percentage of the federal poverty
level, whether individual has a usual source of care, and insurance status. Need factors will
include duration of diabetes and insulin use. As depicted in Figure 2.1, the predisposing variables
impact enabling variables, which impact need variables and all three constructs influence the
likelihood of healthcare utilization.
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Figure 2.1. Conceptual Framework: Andersen’s Healthcare Utilization Model
Through its various provisions that aimed to expand insurance coverage, the ACA was
forecasted to increase rates of health insurance coverage and reduce financial barriers to service
use among millions of at need Americans. Since racial and ethnic minorities are more likely to
be uninsured and lack access to care including preventive screenings (Agency for Healthcare
Research and Quality [AHRQ], 2011; 2017), ACA implementation should have consequently
lessened some of these disparities. Therefore, this study will examine the effects of the ACA
while controlling for predisposing, enabling, and need factors.
The Role of Health Insurance in Addressing Racial and Ethnic Disparities
Health insurance is an important resource for people because it can increase their ability
to obtain necessary medical care and protect them against financial burdens that come with
unexpected medical events. This is particularly true for racial and ethnic minorities who
historically have experienced poorer overall health status compared to whites (Heckler, 1985).
As health insurance is a fundamental component in obtaining positive health outcomes,
particularly in minority populations, much research has been done to understand the impact
health insurance coverage may have in reducing disparities in health services. In a review of the
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literature, Lillie-Blanton and Hoffman (2005) identified articles that answered the question: How
much of racial and ethnic disparities in access to care can be explained by differences in health
insurance status? The review included original research studies that 1) compared whites to a
specific racial and ethnic group (blacks or Hispanics); 2) measured the effects of racial and
ethnic differences in social, economic, or health system factors that may contribute to disparities
in access to health care; and (3) quantified the contribution of racial and ethnic differences in
health insurance on disparities in access to care (Lillie-Blanton & Hoffman, 2005). Four studies
were identified that applied regression-based methods so that multiple factors could be isolated
to determine each factor’s contribution to racial and ethnic disparities in access to care (LillieBlanton & Hoffman, 2005). The studies used several measures of access; however, the measure
of access that was common across all four studies was whether the individual had a usual source
of care. Therefore, the researchers used this as their measure of health care access (Lillie-Blanton
& Hoffman, 2005).
Overall, the studies found both Hispanics and blacks were significantly less likely than
whites to have a usual source of care. However, a larger access gap was seen between Hispanics
and whites than between blacks and whites. Across all four studies, the access gap between
Hispanics and whites ranged between 15 to 16 percentage points, and the access gap between
blacks and whites ranged between 4.4 to 8.4 percentage points (Hargraves & Hadley, 2003;
Waidmann & Rajan, 2000; Weinick et al., 2000; Zuvekas & Taliaferro, 2003). In examining the
contribution of insurance coverage in explaining the access gap, health insurance consistently
explained a significant share (23-33%) of the Hispanic-white access difference and was the
single largest observable factor in all but one study where both health insurance and income
contributed the same share (23%) (Weinick et al., 2000). For three of the four studies, health
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insurance explained 24 to 42% of the black-white access difference. In the Weinick et al. (2000)
study, insurance only accounted for 5%, whereas income accounted for 41% of the access gap.
The only other factor that contributed a sizable share to the black-white access gap was family
structure (26%) (Waidmann & Rajan, 2000). In summary, these studies demonstrated health
insurance accounted for a sizable share of racial and ethnic disparities in access to a usual source
of care (Lillie-Blanton & Hoffman, 2005).
Of the eight comparisons in this review, health insurance explained a statistically
significant share of the access gap in all four comparisons between Hispanics and whites and in
three of the four comparisons between African Americans and whites (Lillie-Blanton &
Hoffman, 2005). The one study that deviated from these otherwise consistent findings is the
Weinick et al. (2000) study which differed in the way it structured its statistical analyses. In that
study, the regression analysis included an interaction term for racial and ethnic characteristics
and insurance status to separate the effect of racial and ethnic differences in health insurance on
access to care (Lillie-Blanton & Hoffman, 2005). In order to examine how differences in
insurance status and income might play a role in explaining racial and ethnic disparities, the
researchers estimated linear probability models with an interaction term between 1) race and
ethnicity and health insurance and 2) race and ethnicity and family income. They then used the
regression estimates to simulate how much of the disparities between Hispanic and whites and
between blacks and whites would change if Hispanics and blacks had health insurance coverage
and income that was equivalent to that of whites (Weinick et al., 2000). The researchers found
that changing the insurance coverage of blacks to be equivalent to that of whites had no
statistically significant impact on the black-white disparity for usual source of care.
Contrastingly, when changing the insurance coverage of Hispanics to match that of white, a 23%
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reduction was seen in the Hispanic-white disparity for usual source of care. Changing the income
of blacks and Hispanics to be equivalent to that of whites resulted in a 41% reduction in the
black-white disparity and 21% reduction and the Hispanic-white disparity in usual source of care
(Weinick et al., 2000).
The remaining three studies utilized a regression decomposition method that allowed
them to decompose the percentages of the total disparity that is associated with differences in the
independent variables of interest. For instance, if the researcher were interested in determining
how much of the total disparity was attributed to racial and ethnic differences in income, the
researcher could simulate the outcome among one racial and ethnic group if that group had the
income distribution of another racial and ethnic group while holding all other characteristics the
same.
The Affordable Care Act
Provisions and Mandates
The Patient Protection and Affordable Care Act, often shortened to the Affordable Care
Act (ACA), was signed into law by President Barack Obama on March 23, 2010. The ACA
attempted to achieve comprehensive health reform by improving health care access, quality, and
cost control (McDonough, 2014; Sealy-Jefferson et al., 2015). The ACA includes numerous
components intended to reduce health disparities, improve the quality of care, and address health
insurance reform among racially and ethnically diverse populations (Andrulis et al., 2010).
Several provisions of the ACA can be expected to have a positive impact on racial and
ethnic minorities. Federal or state government-sponsored health insurance marketplace
exchanges were established to provide private health insurance for individuals who are not
otherwise eligible for Medicaid based on income, age, parenting status or other eligibility
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requirements and who do not have access to employer-sponsored health insurance (McDonough,
2014). Premium tax credits are available to individuals with incomes between 100-400% of the
FPL who purchase health insurance through the marketplace exchange (Frean et al., 2017).
Additionally, cost-sharing subsidies are available to eligible individuals to help reduce the
portion of a claim that the insured will have to pay (KFF, 2012). The ACA health insurance
marketplace exchanges commenced operation in every state on October 1, 2013, and by April
2014, more than 8 million Americans purchased coverage through the ACA health insurance
marketplace (ASPE, 2014).
Another concrete action expected to affect racial and ethnically diverse people include
employer-based health insurance reforms. In 2005, 71 percent of working-age whites had health
insurance through their workplace, whereas only one-third of working-age Hispanics and half of
working-age African Americans had employer-sponsored coverage (Doty & Holmgren, 2006).
With ACA implementation, employers with ≥200 employees are mandated to automatically
enroll employees into their health insurance plans, and employers with ≥50 employees must offer
coverage to employees or pay a penalty for full-time employees that receive a tax credit for
purchasing insurance through the exchanges (Andrulis et al., 2010; French et al., 2016; KFF,
2012). Small employers with fewer than 25 full-time employees with average annual wages of
less than $50,000 qualify for employer tax credits (H.R. 3590, 2010). Given that over 90% of
minority-owned firms are small employers (≤25 employees), and diverse populations are more
likely to be employed by small firms, the employer mandate has the potential to expand coverage
for a sizeable amount of racially and ethnically diverse people (Lowrey, 2007).
Low-income racially and ethnically diverse populations are expected to benefit the most
from the expansion of Medicaid. Medicaid is a federal and state program that provides health
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insurance for many, though not all, low-income Americans (McDonough, 2014). The types of
services offered vary by state; however, states are required by federal law to provide certain
mandatory benefits. Some of these mandatory benefits include early and periodic health
screening, diagnostic, and treatment services, inpatient and outpatient hospital services,
physician services, laboratory and X-ray services, family planning services, transportation to
medical care, nursing facility services, Certified Pediatric and Family Nurse Practitioner
services, and home health services Optional benefits that states may provide include prescription
drugs, prosthetics, eye glasses, physical therapy, occupational therapy, podiatry, optometry,
chiropractic, and dental services (Centers for Medicare & Medicaid Services, n.d.).
Prior to ACA implementation, Medicaid income eligibility limits varied by state with
some states (i.e., Alabama and Texas) setting their income eligibility for Medicaid well below
20% of FPL. As implemented in January 2014, ACA Medicaid expansion extended coverage to
individuals living at or below 138% of the FPL (Sealy-Jefferson, 2015). However, because of the
Supreme Court’s ruling in the National Federation of Independent Business v. Sebelius case,
states have the choice to opt out of implementation, so expansion is not consistent throughout the
U.S. (Rosenbaum & Westmoreland, 2012). As of September 2019, 36 states and the District of
Columbia have adopted Medicaid expansion, whereas 14 states have not (KFF, 2019b). For
states that did not adopt Medicaid expansion, individuals whose incomes are above the Medicaid
eligibility boundary for that state but below the lower limit to receive premium tax credits for
marketplace insurance likely fall into the “coverage gap” and can remain uninsured
(McDonough, 2014).
Along with expanding both public and private insurance coverages, the ACA also
imposed new insurance regulations. For plan years through 2018, the individual mandate
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requires most Americans without employer-sponsored health insurance to obtain health
insurance or pay a penalty; however, Congress reduced the individual mandate penalty to $0
effective in 2019 (Kamal et al., 2018). Young adults can remain under their parents’ health
insurance until the age of 26 (dependent coverage provision). Insurance companies can no longer
deny coverage to individuals based on health status or pre-existing conditions and can no longer
charge more based on gender or health status (KFF, 2012). Insurers must provide comprehensive
health plans that cover essential health benefits which include items and services in the following
ten benefit categories: 1) ambulatory patient services; 2) emergency services; 3) hospitalization;
4) maternity and newborn care; 5) mental health services and substance use disorder services; 6)
prescription drugs; 7) rehabilitative services and devices; 8) laboratory services; 9) preventive
services (i.e., screenings), wellness services, and chronic disease treatment; and 10) pediatric
services (Centers for Medicare & Medicaid Services, n.d.). Lastly, the ACA prohibits insurers
from imposing lifetime limits on coverage and prohibits them from rescinding coverage, except
in cases of fraud (KFF, 2012). Through its various provisions, the ACA intends to make
insurance options available to individuals who may not have been able to afford insurance or had
access to employer-sponsored insurance prior to its implementation.
The ACA and Insurance Coverage by Race and Ethnicity
Analysis of data from the 2013 to 2016 American Community Survey (ACS) found that
since ACA implementation, the proportion of uninsured Americans aged 0 to 64 fell from 17.0
percent to 10.0 percent, meaning 18.5 million more Americans gained health insurance coverage
(Skopec et al., 2018). Of this 18.5 million people, 10.9 million people had Medicaid coverage
and 6.3 million people had private non-group coverage (Skopec et al., 2018). Although both
expansion and non-expansion states saw significant reductions in uninsured rates, states that

41
expanded Medicaid saw a larger reduction in uninsured rates under the ACA. Between 2013 to
2016, the uninsured rate fell by more than 50 percent in Medicaid expansion states with an
additional 12.6 million people gaining coverage of which 9.7 million gained Medicaid coverage
(Skopec, et al., 2018). In non-expansions states, the uninsured rate had a 31 percent decline,
largely due to gains in private non-group coverage and employer-sponsored insurance (Skopec,
et al., 2018). In 2016, uninsured rates for all racial and ethnic groups significantly fell and racial
and ethnic gaps in uninsured rates narrowed. The uninsured rate fell by 8.2, 10.8, and 8.4
percentage points for non-Hispanic blacks, Hispanics, and other or multiple races, respectively,
compared to 5.7 percentage points for non-Hispanic whites (Skopec et al., 2018).
In population-based studies of adults aged 18-64 years, Buchmueller et al. (2016), Chen
et al. (2016), and McMorrow et al. (2015) found the percentage of uninsured adults significantly
decreased for all racial and ethnic groups after implementation of the most significant pieces of
the ACA such as young adult coverage (e.g., adults may remain on a parent’s insurance until the
age of 26 year), marketplace exchanges, and Medicaid expansion; however, there was a larger
decrease for blacks and Hispanics compared to whites (Buchmueller et al., 2016; Chen et al.,
2016). Additionally, there was a significant reduction in both the white-black and white-Hispanic
coverage gaps after the 2014 ACA policy implementation (Buchmueller et al., 2016; McMorrow
et al., 2015).
McMorrow et al. (2015) utilized data from the National Health Interview Survey (NHIS)
to examine changes in insurance coverage disparity gap among blacks, whites, and Hispanics
through December 2014. Measuring absolute disparity (e.g., the difference between percentage
of uninsured white and either the percentage of uninsured blacks or percentage of uninsured
Hispanics) and relative disparity (e.g., the ratio of the percentage of uninsured blacks or
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Hispanics to the percentage of uninsured whites), the study found a significant reduction in both
absolute and relative disparity for black adults and a significant reduction in absolute disparity
for Hispanics (McMorrow et al., 2015). However, when stratifying by state expansion status,
Hispanics experienced a significant increase in relative disparity in expansion states, whereas
blacks experienced a significant decline in relative disparity in non-expansion states. The authors
surmise that the decline in relative disparity for blacks in non-expansion states may be due to
strong Marketplace enrollment and increased participation among those previously eligible for
Medicaid and that the incline in relative disparity for Hispanics in expansion states likely reflects
immigrants’ restricted access to Medicaid and subsidies for Marketplace coverage (McMorrow
et al, 2015). In a complementary study, Buchmueller et al. (2016) investigated the changes in the
source of coverage using data from the 2008-2014 ACS. Findings revealed both private and
public insurance coverages increased more for blacks and Hispanics than for Whites between
2013 and 2014, and coverage gains were greater in states that expanded Medicaid (Buchmueller
et al., 2016).
Additional studies of the ACA’s effects of the Medicaid expansion on racial and ethnic
disparities in insurance coverage found mixed empirical results (Lee & Porell, 2018; Yue et al.,
2018). In a quasi-experimental study examining the low-income (<138% FPL) adult population
using 2013-2015 BRFSS data, Medicaid expansion was associated with a significant increase in
the coverage gap between whites and Hispanics (Yue et al., 2018). Additionally, in a quasiexperimental study of 2011-2016 BRFSS data, Lee and Porell (2018) also saw a widening of the
coverage gap between whites and Hispanics in expansion versus non-expansion states; however,
this result was not statistically significant. Neither study saw a significant change in the coverage
gap between whites and blacks (Lee & Porell, 2018; Yue et al., 2018).
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Both studies have also examined measures of access (e.g., having a usual source of care,
having a personal doctor and being unable to see a doctor due to costs). Yue et al. (2018) found
that Medicaid expansion was associated with an increase in having a personal doctor and a
decrease in being unable to see a doctor due to costs for both non-Hispanic whites and nonHispanic blacks; however, Medicaid expansion was not associated with any improvement in
access outcomes for Hispanics. In fact, for the measure of having a personal doctor, researchers
found that the disparity gap between non-Hispanic whites and Hispanics widened in both
expansion and non-expansion states after ACA implementation. Additionally, although not
statistically significant, an increase was seen in the white-Hispanic disparity for the probability
of being unable to see a doctor due to costs, while a reduction was seen in the black-white
disparity for the same measure (Yue et al., 2018). Similarly, Lee and Porell (2018) did not find
any statistically significant evidence that Medicaid expansion reduced racial and ethnic
disparities in access to care.
The ACA and Diabetic Retinopathy Screening
Although there is a considerable amount of literature that has examined the impact of the
ACA on various health services and health outcomes, few studies have focused on ACA and
racial and ethnic disparities regarding diabetic retinopathy screening. Shi et al. (2016) aimed to
examine potential changes in eye examination rates across different racial and ethnic groups in
adults (aged 18-64 years) with diabetes following ACA implementation. Using data from the
2011 MEPS, the researchers simulated respondent samples for years 2014-2017. Results
revealed that eye examination rates were forecasted to increase for minorities; however, some
racial and ethnic disparities in eye examinations would continue to persist (Shi et al., 2016). The
data simulations used in the study relied on assumptions that population characteristics, diabetes
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prevalence, and other social cultural factors in the predicted years would be the same as in 2011
(Shi et al., 2016). Furthermore, the study did not examine the ACA Medicaid expansion’s role in
reducing racial and ethnic disparities.
In a similar study examining data from MEPS, Monnette, et al. (2019) examined changes
in eye examination rates amongst individuals with diabetes from 2014 to 2015. The study
revealed that eye examination rates significantly increased for both minorities (i.e., respondents
not self-identified as “non-Hispanic white”) and non-Hispanic whites but increased by a greater
amount for minorities. Also, the racial and ethnic disparity between minorities and non-Hispanic
whites was reduced from 2014 to 2015. Although the racial and ethnic disparity between
minorities and non-Hispanic whites was significant in 2014, adjusted models revealed that it was
no longer significant in 2015. Among this study’s limitations was that it only focused on the first
two years after the ACA implementation. Like Shi’s et al. (2016) study, it did not examine the
effects of the ACA Medicaid expansion on racial and ethnic disparities in eye examination rates
among the U.S. adult diabetic population.
The present study intends to extend the research done by Shi et al. (2016) and Monnette
et al. (2019) by 1) examining three full years of data post-ACA implementation; 2) calculating
both absolute and relative disparities for individual racial and ethnic groups and examining how
they have changed over time; and 3) using difference-in-difference analyses to examine the
impact of the ACA Medicaid expansion on racial and ethnic disparities in eye examination rates
among the U.S. diabetes population. At the time of this writing, this study is the first to use three
full years of post-ACA data to estimate the impact of the ACA on racial and ethnic disparities in
eye examination rates in U.S. adults with diabetes and is the first to focus on the effects of the
ACA Medicaid expansion.
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CHAPTER 3-METHODOLOGY
This chapter details the research design and methodology used in the study. The chapter is
divided into sections that include an overview of the research design, data source, study
population, measures, and statistical analyses.
Research Design
A trend analysis was used to examine changes in eye examination rates over time while
adjusting for predisposing, enabling, and need factors. Effects of Medicaid expansion on eye
screening rates were examined using a quasi-experimental research design employing a
difference-in-difference (DiD) analysis, which is used to study causal relationships in public
health settings where randomized controlled trials are infeasible or unethical (Wing et al., 2018).
Prior studies have utilized this design to study the effects of ACA Medicaid expansion by
comparing the changes in health outcomes between the expansion states (treatment group) and
non-expansion states (control group), before and after the policy change (Wherry & Miller,
2016; Yue et al., 2018). Using 2010-2014 National Health Interview Survey data (NHIS) data,
Wherry & Miller (2016) performed a DiD analysis to examine changes in health-related
outcomes (e.g., insurance coverage, physician visits, hospitalizations, diabetes diagnosis, usual
source of care, hypertension, cholesterol) in individuals 19-64 years living below 138% of the
federal poverty level (FPL) residing in expansion states compared to those residing in nonexpansion states. The study has found Medicaid expansion was associated with higher rates of
health insurance coverage and increased utilization of some types of health care. A similar study
of BRFSS data performed a DiD analysis to assess Medicaid expansion impact on access to
primary care use in low-income adults. The study has found Medicaid expansion was associated
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with statistically significant gains in health insurance coverage, having personal doctors, and
affordability (Yue et al., 2018).
Data Source
This study was deemed exempt from review by the investigator’s Institutional Review
Board. We used data from the 2010-2017 Medical Expenditure Panel Survey (MEPS). It
provides national and regional level estimates on health insurance coverage, the frequency of
healthcare utilization, the costs of these services, and sources of payment for the U.S. civilian
noninstitutionalized population (AHRQ, 2018b). MEPS also collects data on respondents’ health
status, demographic and socio-economic characteristics, employment status, access to care, and
comorbidities (AHRQ, 2018b). MEPS employs a panel design in which five rounds of interviews
are collected over two full calendar years. As illustrated below, rounds one and two are
conducted in year one. Round three begins in year one and is completed in year three. Rounds
four and five are conducted in the subsequent year (Figure 3.1). The response rates for MEPS
2010-2017 range from 44.2% to 56.3% (AHRQ, n.d., 2019a).

Figure 3.1. Schematic of Panels/Rounds for 2016 Calendar Year. Adopted from AHRQ (2018a).
The MEPS data consist of a subsample of households that participate in the National
Health Interview Survey (NHIS) which is a nationally representative, cross-sectional household
interview survey sponsored by the Centers for Disease Control and Prevention’s National Center
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for Health Statistics (NCHS). With an annual response rate of approximately 70 percent, NHIS
collects information throughout the year from the civilian, non-institutionalized population.
NHIS contains information on household, family, and individual demographic characteristics, as
well as income, health status and other healthcare related variables (CDC, 2019a).
The NHIS sampling employs an area probability, stratified multistage design (Parsons et
al., 2014). An area probability sample includes geographic areas that are sampled with known
probability (Lavrakas, 2008). In other words, each element in the sampling frame has a known,
nonzero probability of being chosen (Groves et al., 2009, p. 98). Probabilities can be unequal in
that some special populations (e.g., minorities) may have higher chances of being selected than
others. This ensures that there are enough individuals included in the group to prepare separate
estimates for the specified group (Groves et al., 2009, p. 98). For the 2008-2015 NHIS, black,
Hispanic, and Asian persons are oversampled with adults aged 65 or older having a higher
chance of being selected than other adults in the family (Parsons et al, 2014; CDC, 2019a).
The NHIS sampling frame encompasses housing units in place at the time of the 2000
U.S. Census (2008-2015 NHIS) and 2010 U.S. Census (2016 NHIS) (Parsons et al, 2014; CDC,
2019a). In the first stage of sampling, primary sampling units (PSUs) consisting of single
counties or combined contiguous counties are selected from each state. PSUs are then stratified
into Census-defined blocks based on the Census minority concentration status for implementing
differential sampling rates (Parsons et al, 2014). Within each stratum secondary sampling units
are formed consisting of clusters of an expected 8, 12, or 16 sample household units. From each
housing unit, the interview process collects information on the family, sample child (if children
are present), and sample adult (Parsons et al, 2014).
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The MEPS has the same features of the NHIS complex survey design; but unlike the
NHIS, college dorms represent ineligible housing units for MEPS. Analysis using MEPS data
can be undertaken using either the individual or the family as the unit of analysis as a MEPS
household may contain one or more family units, each consisting of one or more individuals
(AHRQ, 2018b). MEPS is sampled from the previous year’s NHIS responding households. For
example, a full calendar year data file for 2016 will contain rounds 3-5 of Panel 20 (which uses
the 2014 NHIS sampling frame) and rounds 1-3 of Panel 21 (which uses the 2015 NHIS
sampling frame) (AHRQ, 2018a).
The Diabetes Care Survey is a component of MEPS that is administered to participants
who answer a “yes” response to the survey question, “was the person ever told by a doctor or
health professional that he/she had diabetes”. The Diabetes Care Survey asks health related
questions such as the number of times hemoglobin was checked, whether the person had feet,
eyes, or blood pressure checked, and whether the person had an influenza vaccination.
Additional questions assess whether the participant treats his/her diabetes with insulin, oral
medications, or diet (AHRQ, 2018b).
For reasons of confidentiality, AHRQ restricts the use of certain MEPS variables
including fully specified International Classification of Diseases (ninth revision) codes, fully
specified industry and occupation codes, state and county federal information processing
standards codes, census tract and block group codes, and federal and state marginal tax rates
(AHRQ, 2019b). This study used restricted-access state identifiers in MEPS, and after approval
by AHRQ, was performed in a NCHS Research Data Center. The RDC provides access to
restricted-use data for statistical purposes while protecting the confidentiality of survey
respondents, study subjects, or institutions (CDC, 2019b).
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Study Population
Inclusion criteria consisted of individuals aged ≥18 years who were diagnosed with
diabetes (n=21,612). Individuals who did not identify as non-Hispanic white, non-Hispanic
black, or Hispanic were excluded (n=2,109). Individuals with missing data on eye examination
(n=4,354), education (n=121), have usual source of care (n=118), insulin use (n=118), and
duration of diabetes (n=412) were excluded from the study bringing the total analytic sample size
to 14,380 observations. For Medicaid expansion analysis, the analyses were further restricted to
individuals living below 138% of the FPL bring the analytic sample size to 4,790 observations.
Measures
Outcome Variable
The outcome for both research questions was operationalized by a survey question on
whether “the respondent reported having an eye exam in which the pupils were dilated in the
survey year”.
Main Independent Variables
The main independent variable for the first research question was race and ethnicity
which included the categories of non-Hispanic white, non-Hispanic black, and Hispanic. The
main independent variable for the second research question was operationalized based on
whether an individual had resided in a state that expanded Medicaid and was conditional on
when the state expanded. The expansion variable was coded as one (expansion) if the survey
respondent’s residential state implemented Medicaid expansion prior to the respondent’s MEPS
interview date. For example, for the states that implemented Medicaid expansion January 1,
2014, the treatment variable was coded as one if the interview occurred after this date. The
expansion variable was coded zero (non-expansion) if the interview date had occurred before
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implementation of Medicaid expansion or if the respondent had resided in a state that did not
expand Medicaid expansion during the study period. During the time of our study period (20102017), 31 states and the District of Columbia implemented Medicaid expansion and 19 states did
not implement Medicaid expansion (Table 3.1).

Table 3.1
ACA Medicaid Expansion Date for Expansion States (KFF, 2019a)
Expansion States (*n=32)
Date of ACA Medicaid
expansion

State

Arizona, Arkansas, California, Colorado,
Connecticut, District of Columbia, Delaware,
January 1, 2014
Hawaii, Illinois Iowa, Kentucky, Maryland,
Massachusetts, New York, North Dakota Ohio,
Oregon, Rhode Island, Vermont, Washington, West
Virginia
Michigan
April 1, 2014
New Hampshire
August 15, 2014
Indiana
February 1, 2015
Alaska
September 1, 2015
Pennsylvania
January 1, 2015
Montana
January 1, 2016
Louisiana
July 1, 2016
Non-expansion States (n=19)
Alabama, Florida, Georgia, Idaho, Kansas, Maine, Mississippi, Missouri, Nebraska,
North Carolina, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah,
Virginia, Wisconsin, Wyoming
Note. *Includes the District of Columbia

Control Variables
As previously described in the literature review section, categorization of the control
variables was informed by the Andersen Healthcare Utilization model. Predisposing factors
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included age, sex, marital status (married/ partnered or single/ never married/ widowed/
divorced/separated) and education (<12 years versus ≥12 years). Prior studies of individuals with
diabetes have shown respondents who are older in age, female, married/partnered, and have a
higher level of education are more likely to obtain eye examinations (Chen et al., 2014;
Monnette et al., 2019; Shi et al., 2014). The enabling factors included economic status (living
below 138% of FPL, living above 138% of FPL insurance status (insured, not insured), whether
respondent has a usual source of care (yes/no), all which have been shown to be associated with
receipt of eye care (Chen et al., 2014; Tran et al., 2017). Need factors included whether the
individual takes insulin (yes/no) and duration of diabetes. As an indicator for diabetes severity,
insulin use has been positively associated with eye examination use (Chen et al., 2014), and
research has shown that duration of diabetes is positively associated with the diabetic retinopathy
prevalence and thus, might influence eye examination utilization (ADA, 2019; Solomon et al.,
2017; Zhao et al., 2014).
Statistical Analyses
All analyses were completed using Stata (version 16; StataCorp, College Station, TX).
The svyset command was used to establish the survey design for the dataset. The MEPS design
variables (STRATA and PSU) were used to account for the complex survey design and
nonresponse and appropriate weights were applied to produce national estimates. Statistical
significance was determined at p<0.05.
Trend Analyses (Research Question #1)
The study population included individuals aged 18 years or older who responded yes to
“having ever been diagnosed with diabetes.” Descriptive statistics of the study population were
calculated for each study year (2010-2017). Tests for trend were performed to determine if the
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study population characteristics changed over time. In crude analyses, weighted proportions of
eye examination were generated for each survey year overall and by race and ethnicity. For each
survey year, a Pearson’s chi-squared test was performed to test differences in the proportion of
eye examinations between each race and ethnicity group. Multivariable logistic regression
models (controlling for the predisposing, enabling, and need factors) followed by the margins
command were used to estimate adjusted prevalence of eye examinations and margins dydx was
used to estimate marginal effects for each covariable.
Medicaid Expansion Analyses (Research Question #2)
The study population included U.S. adults with diabetes living below 138% of the FPL.
Baseline study population characteristics were calculated separately for expansion versus nonexpansion states for 2010 (base study year), 2014 (middle study year), and 2017 (last study year).
A Pearson’s chi-squared test was used to evaluate differences in characteristics of individuals
residing in expansion and non-expansion states. A difference-in-difference (DiD) analysis was
employed to estimate the effects of the ACA Medicaid expansion on eye examination rates. Prior
studies have utilized this design to study the effects of ACA Medicaid expansion by comparing
the changes in outcomes between the expansion group (treatment group) and non-expansion
group (control group), before and after the policy change (Lee & Porell, 2018; Yue et al, 2018).
We estimated the following logistic regression model:
log[ist/1- ist ]=0 + 1Treatmentst + 2Xist + t + s
where log[ist/1- ist ] is the outcome for individual i in state s with a survey date in year t.
Treatmentst is a dummy variable equal to 1 for individuals residing in an expansion state at the
time of the survey interview and 0 otherwise. t represents the year fixed effects, which control
for year-specific characteristics that may change over time, and s represents state fixed effects,
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which control for state-specific time-invariant characteristics. Xist is a vector of individual
characteristics of respondents that include predisposing, enabling, and need factors. The DiD
estimator (1) captured the change in outcome among individuals in Medicaid expansion states
relative to individuals in non-expansion states after the expansion.
DiD relies on the assumption that pre-policy trends are similar in the treatment and
control groups and any post-policy trends are attributable to the policy (Bertrand et al., 2003).
This would hold true if changes in outcomes over time in each group differ by a fixed amount in
every time period and exhibit a common set of period-specific changes (Wing et al., 2018).
Therefore, any observed divergence between expansion and non-expansion states that occurs in
post-policy years can be attributed to the impact of the ACA Medicaid expansions rather than a
pre-existing differential trend (Wherry & Miller, 2016). When this assumption is violated, (e.g.,
when a change occurs in one group but not the other at the same time of the intervention), the
resulting estimates will be biased. The following model was used to assess the parallel trend
assumption:
log[ist/1- ist ] =0 + 1Treatmentst + 2TR + 3Treatmentst*TR + 4Xist
where log[ist/1- ist ] is the outcome for individual i in state s with a survey date in year t.
Treatmentst is a dummy variable equal to 1 for individuals residing in an expansion state at the
time of the survey interview and 0 otherwise. TR is a linear time trend for the period ending in
2013. Xist is a vector of individual characteristics of respondents that includes predisposing,
enabling, and need factors. The estimate for the interaction term between treatment and trend
was found to be nonsignificant at (odds ratio [OR]:0.99, 95% confidence interval [CI]:0.97-1.01,
p=0.585) suggesting no significant difference in pre-expansion trends between expansion and
non-expansion states; this result supported the DiD parallel trends assumption.
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CHAPTER 4-RESULTS
The chapter presents the results obtained from the data analysis. This study examined
trends in eye examination rates among U.S. adults (aged≥18 years) with diabetes, assessed racial
and ethnic differences in eye examination rates, and assessed changes in eye examination rates in
individuals with diabetes living below 138% of the federal poverty level (FPL) in states that
expanded Medicaid compared to those that did not using data from the 2010-2017 Medical
Expenditure Panel Survey (MEPS). Sociodemographic and health-related characteristics are
summarized in Table 4.1.
Description of Study Population
Majority of adults were non-Hispanic white (67.2%), 45-64 years of age (45.1%), women
(50.5%), had ≥12 years education (80.1%), were married or partnered (56.5%), were living at or
above 138% of the FPL (77.2%), were insured (93.3%), had a regular provider (93.3%), were
non-insulin users (69.2%), and reported having diabetes for greater than 10 years (43.7%).
Throughout the study years, the distribution of all characteristics remained the same with the
exception of insurance status (p for trend <0.001), having a usual provider (p for trend =0.046),
and duration of diabetes (p for trend <0.001). There was an overall downward trend in the crude
rate of uninsured adults from 8.9% in 2010 to 6.1% in 2014 (p =0.003) to 4.1% in 2017
(p=0.019) (see Appendix A). The proportion of adults with a usual provider was not stable
across years with the lowest percentages of 92.6% reported in 2012 and 92.5% reported in 2013
and the highest percentages of 94.4% reported in 2011 and 94.5% reported in 2014 (see
Appendix B). There was an overall downward trend in the percentage of adults who had a
diabetes duration of 0-5 years from 36.8% in 2010 to 28.5% in 2017, and an upward trend in the
percentage of adults who had a diabetes duration greater than 10 years from 43.7% in 2010 to
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50.2% in 2017. The percentage of adults with diabetes for 6-10 years remained relatively stable
at 22.8% in 2010 and 21.4% in 2017 (see Appendix C).
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Table 4.1
Characteristics of Adults with Diabetes in the U.S.: 2010-2017 MEPS
All Years
n (%)
14380
8980 (65.5)

2010
n (%)
1594
990 (65.7)

2011
n (%)
1762
1103 (65.7)

2012
n (%)
1947
1222 (66.6)

2013
n (%)
1820
1107 (65.1)

2014
n (%)
1775
1103 (65.3)

Total Sample
Eye Examination
Race and Ethnicity
NH-white
6420 (67.2)
777 (69.0)
835 (67.1)
810 (66.7)
747 (68.0)
745 (67.8)
NH-black
3866 (16.3)
416 (16.1)
486 (16.9)
550 (16.2)
525 (16.1)
509 (16.0)
Hispanic
4094 (16.5)
401 (14.8)
441 (16.0)
587 (17.1)
548 (15.9)
521 (16.2)
Age Group
18 to 44 years
1948 (11.8)
239 (13.8)
270 (14.1)
280 (12.0)
249 (11.0)
238 (10.9)
45 to 64 years
6724 (45.1)
770 (47.2)
830 (47.4)
903 (44.7)
867 (44.3)
814 (43.1)
>=65 years
5708 (43.1)
585 (38.0)
662 (38.5)
764 (43.3)
704 (44.7)
723 (46.0)
Sex
Men
6475 (49.5)
696 (49.3)
788 (50.8)
907 (50.8)
838 (50.0)
761 (46.9)
Women
7905 (50.5)
898 (50.7)
974 (49.2)
1040 (49.2)
982 (50.0)
1014 (53.1)
Education
<12 years
4090 (19.9)
475 (21.5)
541 (21.5)
554 (20.9)
557 (20.6)
481 (17.9)
≥12 years
10390 (80.1)
1119 (78.5)
1221 (78.5)
1393 (79.1)
1263 (79.4)
1294 (82.1)
Marital Status
Married/partnered
7528 (56.5)
832 (57.3)
882 (56.0)
997 (56.6)
933 (56.3)
877 (56.4)
Single
7122 (43.5)
762 (42.7)
880 (44.0)
950 (43.4)
887 (43.7)
898 (43.6)
Economic Status
<138% FPL
4794 (22.8)
524 (23.8)
586 (22.6)
677 (23.8)
616 (22.7)
632 (25.3)
≥138% FPL
9583 (77.2)
1070 (76.2)
1176 (77.4)
1270 (76.2)
1204 (77.3)
1143 (74.7)
*Insured
Uninsured
1289 (6.7)
187 (8.9)
212 (8.4)
238 (8.2)
209 (8.2)
167 (6.1)
Insured
12991 (93.3)
1407 (91.1)
1550 (91.6)
1709 (91.8)
1611 (91.8)
1608 (93.9)
*Has Usual Provider
Yes
13234 (93.3)
1470 (93.3)
1626 (94.4)
1763 (92.6)
1660 (92.5)
1660 (94.9)
No
1146 (6.7)
124 (6.7)
136 (5.6)
184 (7.4)
160 (7.5)
115 (5.1)
Takes Insulin
Yes
4570 (30.8)
493 (30.7)
571 (32.5)
651 (32.1)
589 (30.5)
554 (30.5)
No
9810 (69.2)
1101 (69.3)
1191 (67.5)
1296 (67.9)
1231 (69.5)
1221 (69.5)
*Diabetes Duration
0-5 years
4851 (33.5)
573 (36.8)
644 (35.8)
695 (35.2)
642 (35.4)
598 (34.1)
6-10 years
3257 (22.8)
391 (24.9)
399 (22.4)
443 (22.7)
420 (23.7)
402 (22.8)
>10 years
6272 (43.7)
630 (38.3)
719 (41.8)
809 (42.1)
758 (40.9)
775 (43.1)
Note. Table reports unweighted n's. *Significant for linear trend at p<0.05. NH, non-Hispanic; FPL, federal poverty level.

2015
n (%)
1807
1143 (65.7)

2016
n (%)
1828
1137 (65.2)

2017
n (%)
1847
1175 (64.9)

772 (65.9)
494 (16.9)
541 (17.2)

804 (66.8)
460 (15.9)
564 (17.2)

930 (66.5)
426 (16.5)
491 (17.0)

233 (10.9)
853 (45.3)
721 (43.8)

235 (11.3)
867 (45.2)
726 (43.6)

204 (10.8)
820 (44.1)
823 (45.2)

800 (48.4)
1007 (51.6)

829 (49.3)
999 (50.7)

856 (50.9)
991 (49.1)

490 (18.2)
1317 (81.8)

516 (19.3)
1312 (80.7)

476 (19.7)
1371 (80.3)

937 (59.3)
870 (40.7)

907 (56.8)
921 (43.2)

893 (53.0)
954 (47.0)

586 (21.2)
1221 (78.8)

601 (21.5)
1227 (78.5)

575 (22.1)
1272 (77.9)

135 (5.0)
1672 (95.0)

143 (5.3)
1685 (94.7)

98 (4.1)
1749 (95.9)

1670 (93.4)
137 (6.6)

1677 (92.7)
151 (7.3)

1708 (92.8)
139 (7.2)

549 (29.9)
1258 (70.1)

578 (30.3)
1250 (69.7)

585 (30.3)
1262 (69.7)

593 (33.1)
389 (21.2)
825 (45.6)

568 (30.4)
418 (23.4)
842 (46.2)

538 (28.5)
395 (21.4)
914 (50.2)
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Crude Trends and Racial and Ethnic Differences in Eye Examination Rates
Across 2010-2017, there were no significant changes in the overall study population’s
crude eye examination rates of (p for trend=0.995) (Figure 4.1). Throughout the 8-year study
period, on average 65.5% (95% CI: 64.3-66.7) of U.S. adults with diabetes received an eye
examination (Table 4.1). In 2010, the overall study population’s crude eye examination rate was
65.7% (95% CI: 62.9-68.5) which did not significantly differ from the 2014 (middle study year)
rate (65.3%, 95% CI: 62.2-68.3, p=0.084) or from the 2017 rate (64.9%, 95% CI: 62.1-67.5,
p=0.667). Similarly, no significant trends were noted among non-Hispanic whites, non-Hispanic
blacks, and Hispanics (p for trend=0.984, 0.674, and 0.419, respectively) (Figure 4.1).
Figure 4.1

Figure 4.1. Crude trends in eye examination rates among U.S. adults (age ≥18 years) with
diabetes: MEPS 2010-2017. Error bars represent 95% confidence intervals.
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In examining differences in crude eye examination rates by race and ethnicity, there were
statistically significant differences in the average crude eye examination rates for Hispanics
compared to non-Hispanic whites (58.0%, 95% CI: 55.7-60.2 vs 67.8%, 95% CI: 66.2-69.5,
p<0.001); non-Hispanic blacks compared to non-Hispanic whites (63.4%, 95% CI: 61.4-65.5 vs
67.8%, 95% CI: 66.2-69.5, p<0.001); and Hispanics compared to non-Hispanic blacks (58.0%,
95% CI: 55.7-60.2 vs 63.4%, 95% CI: 61.4-65.5, p<0.001). Except for 2014, a significant
difference in eye examination rates persisted between non-Hispanic whites and Hispanics
throughout the study period (Figure 4.1).
Adjusted Trends and Racial and Ethnic Differences in Eye Examination Rates
Multivariable logistic regression models were used to assess trends and examine racial
and ethnic differences in eye examination rates while controlling for year and state fixed effects,
predisposing factors, enabling factors, and need factors (Table 4.2). When controlling for the
predisposing factors (i.e., age, sex, education, marital status), the average adjusted rates for eye
examination for the overall population did not significantly change throughout the study period
(66.5%, 95% CI: 63.9-69.1 for 2010 vs 65.0%, 95% CI: 62.0-67.3 for 2017) (p for trend=0.913).
The average adjusted rate of eye examination for Hispanics was 2.9 percentage points lower than
that of non-Hispanic whites (65.9%, 95% CI: 64.3-67.7, p=0.047). For each study year, the
adjusted rate of eye examination for Hispanics was significantly lower than that of non-Hispanic
whites. No significant differences were seen in adjusted eye examination rates between nonHispanic whites and non-Hispanic blacks for any of the study years (Figure 4.2a).
In the model adjusting for enabling factors (i.e., insurance status, have a usual provider,
and economic status), the average adjusted rates for eye examination for the overall population
remained relatively unchanged throughout the study period (66.2%, 95% CI: 63.7-68.9 for 2010
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vs 64.3, 95% CI: 61.5-66.9 for 2017) (p for trend=0.931). The average adjusted rate of eye
examination for non-Hispanic whites was 2.7 percentage points and 4.7 percentage points higher
than those of non-Hispanic blacks (64.0%, 95% CI: 62.1-65.9, p=0.029) and Hispanics (61.9%,
95% CI: 59.6-64.3, p=<.001), respectively (Table 4.2). For each study year, the adjusted rate of
eye examination for non-Hispanic whites was higher than that of non-Hispanic blacks and
Hispanics (Figure 4.2b).
The average adjusted eye examination rates for the overall population in the model
controlling for need factors (i.e., insulin use and duration of diabetes) did not significantly
change throughout the study period (66.2%, 95% CI: 63.5-68.9 for 2010 vs 64.0, 95% CI: 61.466.7 for 2017) (p for trend=0.939). For combined study years, the average adjusted rate of eye
examination significantly differed among the races and ethnicities. The average adjusted eye
examination rates for non-Hispanic whites was 4.5 percentage points and 9.5 percentage points
higher than those of non-Hispanic blacks (63.3%, 95% CI: 61.3-65.4, p<.001) and Hispanics
(58.2%, 95% CI: 56.1-60.5, p<.001), respectively (Table 4.2). For each study year, the adjusted
rate of eye examination for non-Hispanic whites was higher than that of non-Hispanic blacks and
Hispanics (Figure 4.2c).
In the model controlling for all predisposing, enabling, and need factors, although a
downward trend was seen in eye examination rates, the average adjusted eye examination rates
for the overall population did not significantly change throughout the study period (67.3%, 95%
CI: 64.8-69.8 for 2010 vs 63.8, 95% CI: 61.2-66.5 for 2017) (p for trend=0.562) (see Appendix
D). Adjusting for all factors eliminated any previous significant differences seen in eye
examination rates between non-Hispanic whites and non-Hispanic blacks and non-Hispanic
whites and Hispanics (Table 4.2, Figure 4.2d).
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Additional fully adjusted models were estimated to assess interactions between race and
ethnicity and insurance status, as well as race and ethnicity and income. Analyses revealed that
there was a different relationship between race and ethnicity and receipt of eye examination for
those who are insured compared to those who are not insured. The difference in eye examination
rates between insured compared to uninsured was significantly higher for non-Hispanic whites
(67.0%, 95% CI: 65.4-68.6 vs 44.4%, 95% CI: 38.1-50.6, p<.001), followed by non-Hispanic
blacks (66.7%, 95% CI: 64.8-68.7 vs 50.6%, 95% CI: 44.0-57.1, p<.001), and Hispanics (65.6%,
95% CI: 63.1-68.0 vs 53.0%, 95% CI: 48.0-58.0, p<.001) (see Appendix E). When assessing the
interaction between race and ethnicity and income, the difference in eye examination rate
between those with incomes ≥138% FPL compared to those with incomes <138% FPL was
significantly higher for non-Hispanic whites (66.8%, 95% CI: 65.1-68.5 vs 61.1%, 95% CI: 58.463.8, p<0.001); no significant differences were seen in non-Hispanic blacks or Hispanics (see
Appendix F).
A likelihood ratio test was used to evaluate differences between the predisposing,
enabling, need, and full models to identify the model which fit the data the best. Based on the
results of the likelihood ratio test, the full model had the better fit compared to each of the
smaller models (models with predisposing, enabling, and need factors; each p<0.001) (see
Appendix G).
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Table 4.2
Adjusted Prevalence of Eye Examination Among U.S. Adults with Diabetes: 2010-2017 MEPS
Model with Predisposing Factors
AAP, %
95% CI
P-value
Year
2010
2011
2012
2013
2014
2015
2016
2017
Race and Ethnicity
NH-White
NH-Black
Hispanic
Age
18 to 44 years
45 to 64 years
>=65 years
Sex
Men
Women
Education
<12 years
≥12 years
Marital Status
Single
Married/partnered
Economic status
<138% FPL
≥138% FPL
Has Usual Provider
No
Yes

Model with Enabling Factors
AAP, %
95% CI
P-value

Model with Need Factors
AAP, %
95% CI
P-value

AAP, %

Full Model
95% CI
P-value

66.5
66.7
66.7
64.8
64.5
65.1
65.0
65.0

63.9-69.1
64.1-69.4
63.8-69.5
62.1-67.5
61.5-67.5
62.4-67.6
62.2-67.7
62.0-67.3

ref.
0.889
0.937
0.375
0.324
0.440
0.429
0.340

66.2
65.8
67.1
65.5
65.0
65.1
65.9
64.3

63.7-68.9
63.1-68.6
64.2-70.0
62.9-68.3
62.2-67.9
62.5-67.6
62.1-67.6
61.5-66.9

ref.
0.830
0.629
0.721
0.555
0.569
0.495
0.307

66.2
65.9
66.8
65.4
65.4
65.6
64.8
64.0

63.5-68.9
63.2-68.5
63.9-69.7
62.7-68.1
62.5-68.4
63.1-68.2
61.9-67.5
61.4-66.7

ref.
0.853
0.752
0.663
0.684
0.771
0.471
0.259

67.3
66.8
67.2
65.6
64.6
64.8
64.6
63.8

64.8-69.8
64.2-69.4
64.4-69.9
63.0-68.2
61.7-67.4
62.3-67.2
61.8-67.3
61.2-66.5

ref.
0.751
0.937
0.351
0.170
0.152
0.152
0.059

65.9
65.8
63.1

64.3-67.6
63.8-67.7
60.9-65.4

ref.
0.880
0.047

66.7
64.0
61.9

64.1-68.2
62.1-65.9
59.6-64.3

ref.
0.029
<.001

67.7
63.3
58.2

66.2-69.4
61.3-65.4
56.1-60.5

ref.
<.001
<.001

65.6
65.6
65.1

64.1-67.1
63.7-67.5
62.8-67.3

ref.
0.960
0.734

49.6
60.5
74.7

46.2-52.8
58.8-62.1
73.1-76.3

ref.
<.001
<.001

53.5
62.1
72.4

50.1-56.7
60.5-63.4
70.1-74.0

ref.
<.001
<.001

64.5
66.3

62.9-66.1
64.7-67.8

ref.
0.082

64.7
66.3

63.266.1
64.8-67.8

ref.
0.094

56.3
67.8

54.0-58.5
66.5-69.1

ref.
<.001

57.6
67.5

55.4-59.9
66.2-68.7

ref.
<.001

61.4
68.6

59.8-63.1
67.1-70.0

ref.
<.001

61.9
68.3

60.3-63.6
66.8-69.6

ref.
<.001

60.8
66.8

58.8-62.8
65.5-68.2

ref.
<.001

62.9
66.2

61.1-64.8
65.1-67.5

ref.
0.002

50.3
66.5

46.1-54.5
65.3-67.7

ref.
<.001

54.5
66.3

50.5-58.6
65.2-67.4

ref.
<.001
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Model with Predisposing Factors
AAP, %
95% CI
P-value

Model with Enabling Factors
AAP, %
95% CI
P-value

Model with Need Factors
AAP, %
95% CI
P-value

AAP, %

Full Model
95% CI

P-value
Insurance Status
Uninsured
42.2
38.4-45.8
ref.
48.9
45.0-52.7
ref.
Insured
67.1
65.9-68.4
<.001
66.7
65.5-67.9
<.001
Takes insulin
No
63.5
62.2-65.1
ref.
62.9
70.0-73.2
ref.
Yes
70.0
68.2-71.7
<.001
71.6
61.5-64.3
<.001
Diabetes Duration
0-5 years
55.8
53.7-57.7
ref.
58.8
56.8-60.7
ref.
6-10 years
67.4
64.9-69.7
<.001
67.3
65.0-69.6
<.001
>10 years
66.5
63.9-69.1
ref.
66.2
63.7-68.9
ref.
72.1
70.6-73.7
<.001
70.0
68.5-71.6
<.001
Note. Reference groups are year=2010, race/ethnicity=NH-whites, age=18-44 years, men, education= ≤12 years, marital status=single, economic status=<138% FPL, usual
provider=no, insurance status=uninsured, insulin use=no, and duration of diabetes=0-5 years. Bold font indicates statistical significance at P<0.05. AAP, average adjusted
prediction; NH, non-Hispanic; CI, confidence interval; ref, reference; FPL, federal poverty level.

Figure 4.2
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Figure 4.2. Adjusted trends in eye examination rates among U.S. adults (age ≥18 years) with diabetes: MEPS 2010-2017. Error bars
represent 95% confidence intervals.
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Medicaid Expansion Analyses
For Medicaid Expansion analysis, we restricted our study population to adults with
diabetes living below 138% of the FPL. The aforementioned adjusted analysis demonstrated a
significant difference in eye examination rates between adults living at or above 138% of the
FPL compared to adults living below 138% of the FPL. The former had 3.3 percentage points
(95% CI: 1.2-5.4) higher eye examination rates compared to the latter (p=0.002) (Table 4.2).
The characteristics of U.S. adults with diabetes living below 138% of the FPL are
summarized for 2010 (base study year), 2014 (middle study year), and 2017 (last study year) by
expansion status (Table 4.3). In 2010, the distribution of all characteristics did not significantly
differ between individuals residing in never-expanding states and states that expanded Medicaid
later on. With the exception of insurance status, no significant differences were observed for
2014 and 2017. Fewer individuals residing in expansion states reported being uninsured
compared to individuals residing in non-expansion states in 2014 (5.4% vs 15.1%, p=0.001) and
in 2017 (2.6% vs 11.0%, p<0.001). By the end of 2014, 26 states and the District of Columbia
expanded Medicaid representing 45.7% of the study population, and as of the end of 2017, 31
states and the District of Columbia expanded Medicaid representing 52.4% of the study
population (Table 4.3).
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Table 4.3
Characteristics of Adults with Diabetes Living below 138 % of the Federal Poverty Level, by Medicaid Expansion Status
2010 (n=524)
Nonexpansion
n (%)
167 (62.2) 140 (57.1)
Expansion
n (%)
Eye examination
Race/ethnicity
NH-white
NH-black
Hispanic
Age group
18 to 44 years
45 to 64 years
>=65 years
Sex
Men
Women
Education
<12 years
≥12 years
Marital Status
Married/partnered
Single
Insurance Status
Uninsured
Insured
Has regular provider
Yes
No
Takes insulin
Yes
No

106 (55.0)
69 (17.8)
110 (27.3)

75 (50.4)
90 (23.4)
74 (26.2)

47 (14.0)
133 (47.4)
105 (38.6)

47 (19.8)
113 (47.0)
79 (33.2)

99 (38.5)
186 (61.5)

72 (33.8)
167 (66.2)

131 (37.7)
154 (62.3)

127 (37.7)
112 (51.9)

100 (31.9)
185 (68.1)

80 (36.6)
159 (63.4)

45 (11.8)
240 (88.2)

44 (17.0)
195 (83.0)

257 (91.2)
28 (8.7)

218 (92.9)
21 (7.1)

94 (33.5)
191 (66.4)

84 (33.4)
155 (66.6)

Pvalue
0.310
0.571

2014 (n=632)
Nonexpansion
n (%)
185 (56.2)
186 (62.1)
Expansion
n (%)

97 (55.4)
87 (16.6)
148 (27.9)

85 (52.9)
128 (25.1)
87 (22.0)

71 (16.9)
140 (42.4)
121 (40.7)

36 (8.2)
138 (43.9)
126 (47.8)

111 (38.2)
413 (63.1)

108 (35.2)
192 (64.8)

181 (61.0)
151 (39)

179 (66.3)
121 (33.7)

110 (37.0)
222 (63.1)

100 (33.9)
200 (66.1)

31 (5.4)
301 (94.6)

51 (15.1)
249 (84.9)

305 (93.2)
27 (6.8)

280 (94.5)
20 (5.5)

118 (40.7)
214 (59.3)

110 (32.3)
190 (67.7)

0.344

P-value

0.249
0.261

2017 (n=575)
Nonexpansion
n (%)
182 (61.4)
151 (52.2)
Expansion
n (%)

125 (53.8)
64 (20.1)
105 (25.1)

89 (49.4)
111 (32.7)
81 (18.0)

45 (15.6)
125 (40.8)
124 (43.6)

29 (14.0)
126 (45.7)
126 (40.3)

107 (40.7)
187 (59.3)

86 (32.1)
195 (67.9)

183 (66.6)
111 (33.4)

170 (71.7)
111 (28.2)

80 (28.1)
214 (71.9)

75 (26.6)
206 (73.4)

10 (2.6)
284 (97.5)

29 (11.0)
252 (88.9)

272 (93.4)
22 (6.6)

254 (88.9)
27 (11.1)

96 (32.3)
198 (67.7)

107 (37.6)
174 (62.4)

0.057

0.308

0.085

0.254

0.412

0.295

0.603

0.129

0.745

0.001

0.441

<.001

0.587

0.975

0.071
0.022

0.651

0.491

0.103

P-value

0.109

0.090

0.249
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Expansion
n (%)

2010 (n=524)
Nonexpansion
n (%)

Pvalue

Expansion
n (%)

2014 (n=632)
Nonexpansion
n (%)

Diabetes duration
0.713
group
0-5 years
97 (34.5)
86 (36.8)
112 (33.7)
98 (30.6)
6-10 years
73 (34.7)
63 (26.8)
68 (21.9)
72 (26.4)
>10 years
115 (40.9) 90 (36.4)
152 (44.4)
130 (43.0)
*
Expansion status, #
0 (0.0)
51 (100.0)
27 (45.7)
24 (54.3)
states (% of population)
Note: Table reports unweighted n's. * Includes the District of Columbia. NH, non-Hispanic

P-value

Expansion
n (%)

2017 (n=575)
Nonexpansion
n (%)

0.559

P-value

0.572
86 (25.2)
60 (21.2)
148 (53.6)
32 (52.4)

80 (27.9)
52 (17.3)
149 (54.8)
19 (47.6)
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Five multivariable logistic regression models were used to estimate treatment effects. The
first model (and each subsequent model) included the treatment dummy variable and controlled
for state and year fixed effects. The second, third, and fourth models were adjusted for
predisposing, enabling, and need factors, respectively, and the fifth model was adjusted for all
factors.
Based on the results of the first model, the adjusted prevalence of eye examination rates
among the study population residing in states that expanded Medicaid was 2.4 percentage points
lower than the rate of those residing in states that did not expand; however, this difference was
not statistically significant (p=0.547) (Table 4.4). Similar nonsignificant results were seen for the
second (predisposing), third (enabling), and fourth (need) models in that the study population
residing in the states that expanded had a lower adjusted prevalence of examinations than those
residing in the states that did not expand (model 2: -2.1 percentage points change, p=0.571;
model 3: -2.5 percentage points change, p=0.513; and model 4: -3.2, p=0.399). The fully
adjusted model also did not find any statistically significant differences in the adjusted
prevalence of eye examination rates in states that expanded versus states that did not expand
Medicaid (59.4, 95% CI: 56.8-62.1 vs 56.4, 95% CI: 50.9-62.0, p=0.413) (Table 4.4). Further, no
significant interaction was seen between expansion status and race and ethnicity which suggests
that changes in eye examination rates did not significantly differ in expansion versus nonexpansion states for non-Hispanic whites (-6.0 percentage points change, p=0.210), non-Hispanic
blacks (1.6 percentage points change, p=0781) and Hispanics (-2.0 percentage points change,
p=0.698).
A likelihood ratio test was used to evaluate differences between the predisposing,
enabling, need, and full models to identify the model which fit the data the best. Based on the
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results of the likelihood ratio test, the full model had the better fit compared to each of the
smaller models (models with predisposing, enabling, and need factors; each p<0.001) (see
Appendix G).
Sensitivity analyses were performed to examine whether changes in eye examination
rates differed by level of exposure to Medicaid expansion. Three different treatment variables
were used in fully adjusted models: 1) years since expansion modeled as a continuous variable,
2) treatment with a 1-year post-expansion lag, and 3) treatment with a 2-year post-expansion lag.
We did not find any significant changes in eye examination rates for any of the treatment
variables (model 1-OR:1.1, 95% CI: 0.9-1.2, P=0.346; model 2-OR:1.1, 95% CI: 0.8-1.6,
p=0.508; model 3-OR: 1.3, 95 % CI: 0.9-1.8, P=0.099 (see Appendix H).
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Table 4.4
Changes in Eye Examination Rates among Diabetic Respondents Living below 138% of the Federal Poverty Line, Before and After Medicaid Expansion
Model 1
AAP

95% CI

Model 2
Pvalue

AAP

95% CI

Model 3
Pvalue

AAP

95% CI

Model 4
Pvalue

AAP

95% CI

Model 5
Pvalue

AAP

95% CI

Pvalue

Treatment Effects
Non-Expansion
59.3 56.4-62.1
ref.
59.2
56.4-61.9
ref.
59.3
56.5-62.1
ref.
59.5
56.7-62.2
ref.
59.4
56.8-62.1
ref.
Expansion
56.8 50.9-62.7 0.547 57.1
51.4-62.7 0.572 56.8
51.0-62.5
0.513 56.3
50.5-62.0 0.399 56.4
50.9-62.0 0.413
Race and ethnicity
NH white
57.9
54.9-60.8
ref.
57.5
54.7-60.2
ref.
NH black
59.9
56.5-63.3 0.397
59.2
55.7-62.6 0.477
Hispanic
58.9
55.2-62.7 0.666
60.4
56.6-64.2 0.242
Age
18 to 44 years
44.5
40.1-49.1
ref.
49.2
44.4-53.9
ref.
45 to 64 years
53.8
51.2-56.4 <.001
55.4
52.8-58.0 <.001
>=65 years
69.6
66.8-72.4 <.001
55.1
63.2-69.0 <.001
Sex
Men
56.3
53.4-59.2
ref.
57.1
54.2-59.8
ref.
Women
60.1
57.8-62.4 0.036
59.6
57.4-61.7 0.138
Education
<12 years
54.3
51.3-57.2
ref.
54.6
51.6-57.4
ref.
≥12 years
61.2
58.9-63.4 <.001
61.1
58.9-63.1 <.001
Marital Status
Married/partnered
61.1
58.1-64.1
ref.
61.7
58.7-64.6
ref.
Single
57.3
54.9-59.7 0.058
57.1
54.8-59.4 0.017
Has Usual Provider
No
43.3
37.3-49.3
ref.
47.6
41.4-53.8
ref.
Yes
60.2
58.2-62.1
<.001
59.7
57.9-61.7 <.001
Insurance Status
Uninsured
38.8
33.4-44.1
ref.
44.7
39.1-50.3
ref.
Insured
61.1
59.1-63.2
<.001
60.4
58.4-62.5 <.001
Takes Insulin
No
56.8
54.4-59.2
ref.
56.2
54.1-58.4
ref.
Yes
61.9
58.9-64.9 0.008 62.9
60.0-65.8 <.001
Diabetes Duration
0-5 years
48.4
45.4-51.4
ref.
51.9
48.9-55.0
ref.
6-10 years
56.0
52.2-59.8 <.001 56.5
52.7-60.3 0.057
>10 years
67.4
64.7-69.9 <.001 64.7
62.1-67.3 <.001
Note. Reference groups are year=2010, race/ethnicity=NH-whites, age=18-44 years, men, education= ≤12 years, marital status=single, usual provider=no, insurance
status=uninsured, insulin use=no, and duration of diabetes=0-5 years. Bold font indicates statistical significance at P<0.05. All models adjust for state and year fixed effects.
Model 2 adjust for predisposing factors. Model 3 adjusts for enabling factors. Model 4 adjusts for need factors. Model 5 adjusts for all factors. NH, non-Hispanic; CI,
confidence interval; AAP, average adjusted predictions; ref, reference.
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CHAPTER 5-DISCUSSION
This chapter summarizes findings and places them in the context of existing and future state of
research and practice, given the study’s limitations and strengths. This research examined trends in eye
examinations among U.S. adults (aged≥18 years) with diabetes, assessed racial and ethnic differences in
eye examination rates, and assessed changes in eye examination rates in individuals with diabetes living
below 138% of the federal poverty level (FPL) in states that expanded Medicaid compared to those that
did not. This study utilized data from the 2010-2017 Medical Expenditure Panel Survey. Trend analyses
and multivariable logistic regression analyses were used to answer two specific research questions: (1)
Are there racial and ethnic disparities in eye examination rates among U.S. adults (age≥18 years) with
diabetes across 2010-2017? (2) Is ACA Medicaid expansion associated with changes in eye examination
rates among U.S. adults with diabetes living below 138% of the federal poverty level (FPL)?
Summary of Findings
Crude Trends and Racial and Ethnic Differences in Eye Examination Rates
Studies on recent trends in eye examination rates examined by race and ethnicity are scarce in
the literature. To the best of our knowledge, the present study is the first to examine trends in racial and
ethnic disparities in eye examination rates among U.S. adults (age≥18 years) with diabetes across 20102017. This study found no significant trends in crude eye examination rates for the overall study
population or for non-Hispanic whites, non-Hispanic blacks, and Hispanics. Similarly, a study based on
data from the 2001-2010 Behavioral Risk Factor Surveillance System (BRFSS) also found no significant
trends in crude eye examination rates for the overall population, non-Hispanic blacks, or Hispanics, but
found an overall decreasing trend in eye examination rates for non-Hispanic whites (Chen et al., 2014).
Shi et al. (2014) found the opposite in their study based on 2002-2009 MEPS data: non-Hispanic whites
had a significant upward trend in eye examination rates. The overall crude eye examination rates of 60-
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67% reported in their study is consistent with our study’s rates of 64-66% indicating that the annual eye
screening rates have remained relatively stable over time.
In unadjusted analysis of racial and ethnic differences in eye examination rates, the present study
found that overall, the crude eye examination rate in non-Hispanic whites was significantly higher than
the crude eye examination rates in non-Hispanic blacks and Hispanics. The findings in this study are
similar to those of other studies in that crude eye examination rates were higher for non-Hispanic whites
compared to Hispanics (Lee et al., 2006; Shi et al., 2014) and for non-Hispanic whites compared to nonHispanic blacks (Lee et al., 2006; Shi et al., 2014).
Adjusted Trends and Racial and Ethnic Differences In Eye Examination Rates
This study used multivariable logistic regression to control for predisposing, enabling, and need
factors while assessing trends and racial and ethnic differences in eye examination rates. Similar to
unadjusted analysis, adjusted analyses found no significant trends in eye examination rates for the
overall population or for non-Hispanic whites, non-Hispanic blacks, and Hispanics.
In the models adjusting for enabling and need factors, non-Hispanic blacks and Hispanics were
less likely to report eye examinations compared to non-Hispanic whites. However, in the model
adjusting for predisposing factors, Hispanics were the only group less likely to report eye examinations
compared to non-Hispanic whites. This suggest that the predisposing model contains confounding
factors that distort the relationship between the race and ethnicity and eye examination rates due to 1)
their association with eye examination rates and 2) their uneven distribution among the racial and ethnic
groups. For example, research has shown that black Americans display lower marriage rates than do
other racial and ethnic groups (Bramlett & Mosher, 2001; Martin et al., 2014; Raley et al., 2015; Sweeny
& Phillips, 2004) and high school dropout rates remain the highest among Latinos, followed by AfricanAmericans and then Whites (Kena et al., 2015). Our findings support this research in that a greater
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proportion of Hispanics (45.7%) had <12 years education compared to non-Hispanic whites (13.5%) or
non-Hispanic blacks (19.9%) and a greater proportion of non-Hispanic blacks (60.6%) were single
compared to non-Hispanics whites (39.4) and Hispanics (43.6%) (see Appendix I). Additionally, both
education and marital status were significantly associated with the outcome in adjusted models.
Specifically, adults who were married had a 6.3 pps higher rate of eye examination compared to adults
who were single (p=<.001) and adults with ≥12 years of education had a 9.8 pps higher rate of eye
examination compared to adults with <12 years of education (p=<.001; Table 4.2). Therefore, in
controlling for these factors, a more accurate relationship between and ethnicity and receipt eye
examination can be observed.
In the model adjusting for all factors (predisposing, enabling, and need), no significant
differences were found in eye examination rates by race and ethnicity. Our findings are consistent with
Monnette et al.’s (2014) study of 2014-2015 MEPS data which also did not find significant differences
in eye examination rates by race and ethnicity. A study of 2002-2013 MEPS data also found there was
no association between race and ethnicity and receipt of eye examination in a model adjusting for age,
sex education, insurance status, economic status, diabetes care measures, and vision and general health
measures (Tran et al., 2017). However, our results differ from those reported in Chen et al.’s study
(2014). In Chen et al.’s (2014) study of 2001-2010 MEPS data, their adjusted model was most
comparable to our fully adjusted model in that it adjusted for eight out of nine of our predisposing,
enabling, and need factors (did not adjust for duration of diabetes). In their adjusted model, race and
ethnicity remained significantly associated with receipt of eye examination; non-Hispanic blacks and
Hispanics were more likely to obtain an eye examination than non-Hispanic whites.
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Medicaid Expansion Analyses
There have been limited prior studies examining the effects of the ACA on changes in eye
examination rates. In this study, Medicaid expansion was not associated with changes in eye
examination rates in any of the multivariable logistic regression analyses. In Chen et al.’s (2020) quasiexperimental study using 2009-2017 BRFSS data, results of DiD analysis (adjusted for age, sex, and
race) revealed that Medicaid expansion was associated with a significant increase in eye examination
rates for the 2014-2015 period but was no longer associated with changes in eye examination rates for
the cumulative study periods of 2014-2016 and 2014-2017. The lack of association between Medicaid
expansion and changes in eye examination rates could be influenced by changes in provider availability.
With improvements in insurance access, there may not be enough eye care specialist available to meet
the demand of the increased number of newly insured patients requiring eye examinations. Recent
studies reported increased difficulty of obtaining a specialist appointment in 2016 compared to 2014 or
2015 (Sommers et al., 2017) and significantly longer wait times for low-income adults in expansion
states (Miller & Wherry, 2017). Limited eye care specialist availability is plausible considering that
60.7% of counties in the U.S. are in the lowest two quartiles for ophthalmologist and optometrist
availability (Gibson, 2015).
Study Limitations
This study had several limitations. First, the MEPS diabetes care survey only collects
information on the dilated eye examinations but does not collect information on other forms of diabetic
retinopathy screening such as validated retinal photography used in telemedicine. However, dilated eye
examination is still considered the gold standard for diabetic retinopathy screening, so the rates should
be most relevant to quality of care for diabetes (ADA, 2019). Second, due to the phrasing of the
outcome question which asks responders if they have had a dilated eye examination within the survey
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year, it is possible to underestimate the prevalence of dilated eye examination. Respondents might not
have obtained their annual eye examination at the time that the MEPS interview was conducted.
Therefore, cases could be missed if the respondent obtained an eye examination following the MEPS
interview. Third, MEPS does not include a measure for whether respondents have prediabetes or
undiagnosed diabetes. As of 2018, 7.3 million adults (age≥18years) in the U.S. had undiagnosed
diabetes and 88 million adults had prediabetes (CDC, 2020a). Therefore, underreporting of diabetes
prevalence is possible. Fourth, if a large proportion of the study respondents enrolled in Medicaid prior
to expansion, then the effect of Medicaid expansion might be underestimated. We partially controlled
for this effect by including non-expansion states that likely had similar cross-sections of survey
respondents and by including insurance status as a control variable in adjusted models.
Public Health Implications
Although there are effective treatments available to prevent and even reverse vision loss from
diabetic retinopathy, it still remains one of the leading causes of preventable blindness in the U.S. (CDC,
2018; Cheung, Mitchell, & Wong, 2010; Leasher et al., 2016). It is important that diabetic retinopathy
screening programs are tailored to target those at highest risk and who are least likely to obtain
screening. In order to create a successful screening program, it is important to understand the factors that
influence whether an individual obtains screening. This study provides evidence that trends in dilated
eye examination rates remained relatively stable; racial and ethnic disparities in eye examination rates
are no longer apparent after controlling for predisposing, enabling, and need factors, and Medicaid
expansion was not associated with changes in eye examination rates.
The U.S. Department of Health and Human Services’ Healthy People goals of vision includes
increasing the proportion of people who have an annual dilated eye examination to 58.7% for 2020 and
67.6% for 2030 (ODPHP, 2020b, 2020c). Our study found that overall rates were 64-66% implying that
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the adult diabetes population has consistently met the 2020 goal. Although not significant, our study did
find a slight downward trend in rates, so whether eye examination rates will meet the 2030 goal over the
next decade is uncertain.
Although lack of health insurance has been identified as a major barrier to individuals obtaining
necessary medical care including diabetic retinopathy screenings (Ellish, Royak-Schaler, & Passmore et
al., 2007; Lu et al., 2016; Owsley et al., 2006; Paz et al., 2006; Shi et al., 2014; Walker et al., 1997), our
analysis examining the role of Medicaid expansion on eye examination rates found no significant
differences in eye examination rates between individuals residing in an expansion versus non-expansion
states suggesting that increases in insurance access alone may not be sufficient in improving dilated eye
examination rates. Our results based on fully adjusted DiD models showed that several of the
predisposing, need, and enabling factors (i.e., age, education, marital status, has usual provider,
insurance status, takes insulin, and duration of diabetes) were related to receipt of eye examination.
Thus, future research on policies or programs aimed at addressing other influencing factors may be
warranted to improve dilated eye examination rates.
For instance, health literacy regarding the need for a dilated eye examination was identified as a
major barrier of diabetic retinopathy screening (Graham-Rowe et al., 2018; Liu & Swearingen, 2017;
Piyasenya et al., 2019; Lindenmeyer et al., 2014; Srinivasan et al., 2017). The U.S. Department of
Health and Human Services defines health literacy as “the degree to which individuals have the capacity
to obtain, process, and understand basic health information needed to make appropriate health
decisions” (Koh, 2010; ODPHP, 2020d). Persons with adequate health literacy are more likely to take
responsibility for their health and for their family’s health (ODPHP, 2020d). Those at risks for reduced
levels of health literacy include individuals with lower education levels and racial and ethnic minorities
(Cutilli & Bennet, 2009; Fathy et al., 2016; Kutner et al., 2006). In a study using data from the 2003
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National Assessment of Adult Literacy (NAAL), almost half of adults who did not graduate from high
school had low health literacy (Kutner et al., 2006). Our study saw that a significantly higher proportion
of Hispanics compared to non-Hispanic whites had <12 years of education (45% vs 13%, p<.001) (see
Appendix 9). Previous research supports that Hispanics have the highest high school dropout rates
followed by blacks and whites (Kena et al., 2015). Therefore, it is probable that the difference in
education level may be associated with the respondents’ level of health literacy regarding diabetes care
and thus, contribute to the respondents’ non-adherence to diabetic retinopathy screening guidelines.
Interventions aimed at improving patient knowledge regarding diabetic retinopathy and screening should
be tailored to match different levels of education.
In addition to low health literacy, the lack of a health care provider’s recommendation for eye
screening has also been identified as a barrier of diabetic retinopathy screening (Dervan et al., 2008;
Kashim, Newton, & Ojo, 2018; Van Eijk et al., 2012). Primary care providers play a vital role in
diabetic eye care as they can educate, recommend, and refer patients to eye specialist for screening (Liu
& Swearingen, 2017). Primary care providers do not directly perform diabetic retinopathy screening but
may have greater access to patients with diabetes than do eye care providers because at least 90% of US
patients diagnosed with diabetes are treated by primary care physicians (Davidson, 2010; Liu &
Swearingen, 2017). Therefore, they can influence more patients with diabetes to have eye screening
through their recommendation. However, limited access to a usual primary care provider can reduce
opportunities for screening recommendations. Our study found that a greater proportion of persons with
a usual provider had an eye examination compared to persons without a usual provider (66.3% vs
54.5%, p=<.001; Table 4.2). Interventions should target improving access to primary care providers for
vulnerable populations that will benefit most from diabetic retinopathy screening. Practices to improve
access to care include addressing illiteracy and low health literacy among patients, identifying cost-
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effective resources for patients, and helping patients find the least expensive options for transportation,
insurance, and medication (Toscos et al., 2018).
Opportunities for Future Research
Although screening as met the 2020 target and appears to remain stable over the past decade,
improving screening rates continues to be a priority objective of 2030 healthy people. Improving
screening rates will require more creative methods for health care delivery as access to care continues to
be a barrier for many. Access to eye care specialists has been identified as a barrier of diabetic
retinopathy screening (Lindenmeyer et al., 2014; Liu & Swearingen, 2017) and is also often limited by
geographic, economic, cultural, educational, and other factors (Cavallerano & Conlin, 2008; Hartnett, et
al., 2005; Gower et al., 2013). Studies have shown that residents in areas with a low density of eye care
professionals are less likely to have an annual eye examination (Chou et al., 2012; Resnikoff et al.,
2012). A study of BRFSS data linked to the Area Resource File found that individuals residing in
counties with less than 20 eye care professionals/100,000 people were less likely to report having had a
dilated eye examination in the past year than those with 20 or more ECPs/100,000 people (Chou et al.,
2012). Further, analyses of data from the 2011 Area Health Resources File demonstrated that 24.0% of
the 3143 US counties had no ophthalmologists or optometrists (Gibson, 2015) and many of these
counties are rural areas where long travel distances have been shown to negatively affect adherence to
diabetic eye screening (Chen et al., 2020; Liu et al., 2018) supporting the notion that the distribution of
optometrists in the US is not conducive to the coverage of remote areas (Gupta et al., 2017).
Telemedicine screening for diabetic retinopathy has the potential to provide screening services to
areas where optometrists or ophthalmologist are scarce, thus, enabling individuals who live in these
areas to have greater access to diabetic retinopathy screening services (ADA, 2019, p. 129). This
strategy involves digital retinal photography with remote reading by an eye specialist and is considered
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an appropriate alternative method for diabetic retinopathy screening (ADA, 2019, p. 129). Studies
evaluating the United Kingdom’s Diabetic Eye Screening Program (DESP), which uses telemedicine to
enable broader coverage, have shown that the program was successful in increasing the annual uptake of
diabetic eye screening (Public Health England, 2017; Scanlon, 2017; Sim et al., 2016). As telemedicine
programs continue to evolve and expand, future studies should 1) examine the effects of telemedicine on
uptake and adherence to diabetic retinopathy screening guidelines, particularly in vulnerable populations
and areas with a low density of eye care specialists, 2) examine the costs-effectiveness of the
telemedicine approach compared to the traditional optometry/ophthalmology approach, and 3) how
effective is it in detecting and preventing adverse eye outcomes.
Prior studies and the present study used survey data to examine the association of Medicaid
expansion on changes in eye examination rates in low-income adults with diabetes. However, the use of
other data sources (e.g., administrative records) to examine this topic would enhance this body of
research. Future research could examine changes in visits to eye care specialist, changes in eye carerelated provider visits, costs and reimbursements in diabetic adults residing in expansion versus nonexpansion states
Conclusions
Diabetic retinopathy is a treatable condition if caught early, yet many of individuals forego
screening, which can lead to the development of vision loss and/or blindness. This study provided
critical insight into the present trends (8-year avg rate: 65.0 %) in diabetic retinopathy screening that
have remained relatively stable across 2010-2017, how those trends measure up to the national vision
care targets of 58.7% (2020) and 67.6% (2030), and seemingly no differences in diabetic retinopathy
screening between non-Hispanic whites, non-Hispanic blacks, and Hispanics when adjusting for
predisposing (age, sex, education, marital status), enabling (economic status, insurance status, usual
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provider), and need factors (insulin use, duration of diabetes). Additionally, it provided insight on the
effects of Medicaid expansion on eye examinations in diabetic adults living below 138% of the FPL.
Based on the study’s findings, insurance coverage may be necessary to access regular eye care among
diabetic patients, but it may not be sufficient. Continued advancement in the delivery of screening for
diabetic patients will be necessary to improve their overall eye care.
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APPENDICES

A Crude Trend in Insurance Rate among U.S. Adults with Diabetes

Appendix A. MEPS 2010-2017. Error bars represent 95% confidence intervals.
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B Crude Trend in Usual Provider for U.S. Adults with Diabetes

Appendix B. MEPS 2010-2017. Error bars represent 95% confidence intervals.
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C Crude Trend in Duration of Diabetes for U.S. Adults with Diabetes

Appendix C. MEPS 2010-2017. Error bars represent 95% confidence intervals.
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D Eye Examination Rates for U.S. Adults with Diabetes

Appendix D. Adjusted trend in eye examinations for U.S. adults (age ≥18) with diabetes: MEPS 20102017. Error bars represent 95% confidence intervals.
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E Adjusted Model with Race and Ethnicity*Insurance Status Interaction Term
AAP

95% CI

AME

p-value

NHW

65.5

64.0-67.0

Ref.

Ref.

NHB

65.6

63.8-67.5

0.1

0.904

Hispanic

64.7

62.3-67.0

-0.8

0.583

Uninsured

46.8

42.1-51.4

Ref.

Ref.

Insured

66.7

65.5-67.9

19.9

<.001

NHW*Uninsured

44.4

38.1-50.6

Ref.

Ref.

NHW*Insured

67.0

65.4-68.6

22.6

<.001

NHB*Uninsured

50.6

44.0-57.1

Ref.

Ref.

NHB*Insured

66.7

64.8-68.7

16.2

<.001

Hispanic*Uninsured

53.0

48.0-58.0

Ref.

Ref.

Hispanic*Insured

65.6

63.1-68.0

12.5

<.001

Race and ethnicity

Insurance status

NHW*Insurance Status

Note. All models were adjusted for year, age, sex, education, marital status, insurance status, economic
status, have usual source of care, insulin use, and duration of diabetes. AAP, average adjusted
prediction; AME, average marginal effects NHW, non-Hispanic white; NHB, non-Hispanic black; CI,
confidence interval; ref, reference
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F Adjusted Model with Race and Ethnicity*Economic Status Interaction Term
AAP

95% CI

AME

p-value

NHW

65.6

63.9-66.9

Ref.

Ref.

NHB

65.5

63.5-67.5

0.1

0.967

Hispanic

64.6

62.2-66.9

-0.1

0.546

<138% FPL

62.3

60.3-64.3

Ref.

Ref.

≥138% FPL

66.2

64.9-67.5

3.9

<.001

NHW*<138% FPL

61.1

58.4-63.8

Ref.

Ref.

NHW*≥138% FPL

66.8

65.1-68.5

5.6

<.001

NHB*<138% FPL

63.9

60.9-66.8

Ref.

Ref.

NHB*≥138% FPL

66.0

63.5-68.5

2.2

0.273

Hispanic*<138% FPL

65.5

62.4-68.5

Ref.

Ref.

Hispanic*≥138% FPL

64.3

61.5-67.1

-1.2

0.543

Race and ethnicity

Economic status

NHW*Economic status

Note. All models were adjusted for year, age, sex, education, marital status, insurance status, economic status,
have usual source of care, insulin use, and duration of diabetes. AAP, average adjusted prediction; AME, average
marginal effects NHW, non-Hispanic white; NHB, non-Hispanic black; CI, confidence interval; ref, reference
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G Likelihood Ratio Tests
Degrees of
Freedom

Chi-square

p-value

Full vs Predisposing

6

553.12

<.001

Full vs Enabling

8

644.64

<.001

Full vs Need

8

782.42

<.001

Full vs Predisposing

5

197.27

<.001

Full vs Enabling

8

200.80

<.001

Full vs Need

7

199.98

<.001

Trend Analysis

Medicaid Expansion Analysis
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H Sensitivity Analyses

AOR
Treatment Effects
Model 1
Years since expansion 1.1
Model 2
Expanded-1-year lag
1.1
Model 3
Expanded-2-year lag
1.3

95% CI

P-value

0.9-1.3

0.263

0.8-1.6

0.508

0.9-1.8

0.099

Note. Reference category for each treatment variable was no expansion. All models
were adjusted for age, sex, race and ethnicity, education, marital status, insurance
status, have usual source of care, insulin use, duration of diabetes and state and year
fixed effects. AOR, adjusted odds ration; CI, confidence interval.
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I Distribution of Population Characteristics by Race and Ethnicity
Trend Sample (n=14,380)
Medicaid Sample (n=4,790)
NHNH
NHblacks,
Hispanics,
whites,
blacks,
Hispanics,
%
%
p-value %
%
%
p-value
Age
<.001
<.001
18 to 44 years
9.4
15.3
17.9
12.2
16.8
19.7
45 to 64 years
43.4
48.4
49.0
44.0
47.7
45.6
>=65 years
47.2
36.3
33.1
43.8
35.5
34.7
Sex
<.001
0.027
Men
51.8
42.4
47.5
39.1
34.4
41.2
Women
48.2
57.6
52.5
60.9
65.6
58.8
Education
<.001
<.001
≥12 years
86.5
80.1
54.3
72.1
68.7
38.5
<12 years
13.5
19.9
45.7
27.9
31.3
61.5
Marital Status
<.001
<.001
Single
39.4
60.6
43.6
33.3
21.5
45.6
Married/partnered 60.6
39.4
56.4
66.7
78.5
54.4
Economic status
<.001
<138% FPL
17.2
32.8
35.9
n/a
n/a
n/a
≥138% FPL
82.8
67.2
65.1
n/a
n/a
n/a
Has Usual Provider
<.001
<.001
No
5.4
6.9
88.5
8.4
8.1
12.5
Yes
94.6
93.1
11..5
91.5
91.9
87.5
Insurance Status
<.001
<.001
Uninsured
4.4
6.6
16.3
6.9
10.0
21.6
Insured
95.6
93.4
83.7
93.1
90.0
78.4
Takes insulin
<.001
<.001
No
69.5
68.3
68.9
64.0
61.5
65.0
Yes
30.5
31.7
31.1
36.0
38.5
35.0
Diabetes Duration
<.001
<.001
0-5 years
33.2
33.4
34.9
32.0
32.0
32.7
6-10 years
22.6
22.8
23.2
21.7
21.7
21.6
>10 years
44.2
43.8
41.9
46.3
46.3
45.7
Note. P<0.05 considered statistically significant. N/a, not applicable; NH, non-Hispanic; FPL, federal poverty
level
NH
whites,
%

